



Changes to State Controlled Substance Schedules: Bill Status Update

Research current through March 24, 2015.

This project was supported by Grant No. G1399ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Alabama	No pending proposed regulations. The state's official controlled substances list is published here and was last updated on January 21, 2015. The controlled substances list is also published as the Appendix to Ala. Admin. Code r. Ch. 420-7-2.	N/A
Alaska 2015 HB 51	Adds tramadol and related substances to Schedule IVA.	1/21/2015 – referred to Judiciary Committee.
Alaska 2015 HB 79	Adds hashish, hash oil and hashish oil to Schedule VIA.	3/9/2015 – hearing in Judiciary Committee scheduled.
Arizona 2015 HB 2139 (Page 1 of 4)	<p>Adds the following substances to Schedule I:</p> <ul style="list-style-type: none"> (1) Acetylmethadol; (2) 3, 4-methylenedioxy-N-ethylamphetamine (N-ethyl MDA, MDE, MDEA); (3) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy MDA); (4) 5-methoxy-N,N,-dimethyltryptamine (5-MeO-DMT); (5) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT); (6) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe, Cimbi-5); (7) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe, Cimbi-82); (8) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe, Cimbi-36); (9) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48); (10) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22); 	3/17/2015 – signed by Governor.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Arizona</p> <p>2015 HB 2139 (continued) (Page 2 of 4)</p>	<p>Adds the following substances to Schedule I:</p> <ul style="list-style-type: none"> (11) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22); (12) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA); (13) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA); (14) Alpha-methylaminovalerophenone (Pentedrone); (15) N-benzylpiperazine (BZP); (16) 3-fluoro-N-methylcathinone (3-FMC); (17) 4-fluoro-N-methylcathinone (4-FMC, Flephedrone); (18) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP); (19) 4-methyl-N-ethylcathinone (4-MEC); (20) Naphthypyrovalerone (Naphyrone); (21) N,N-dimethylamphetamine. <p>Adds the following substances to Schedule II:</p> <ul style="list-style-type: none"> (1) Dihydroetorphine; (2) Oripavine; (3) Fentanyl immediate precursor, 4-anilino-N-phenethyl-4-piperidine (ANPP); (4) Tapentadol. (5) Phenylacetone; (6) Lisdexamfetamine, and its salts, isomers and salts of isomers; (7) Nabilone. <p>Removes the following two combination products from Schedule III :</p> <ul style="list-style-type: none"> (1) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of isoquinoline alkaloid of opium; and (2) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts. 	<p>3/17/2015 – signed by Governor.</p>

Yellow highlighted text indicates legislation that has been enacted into law.
Red text indicates that the legislature presently is not in session.
Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Arizona</p> <p>2015 HB 2139</p> <p>(Continued)</p> <p>(Page 3 of 4)</p>	<p>Adds the following substances to Schedule III:</p> <ol style="list-style-type: none"> (1) Embutramide; (2) Perampanel, and its salts, isomers and salts of isomers; (3) 3beta, 17-dihydroxy-5a-androstane; (4) 3alpha, 17beta-dihydroxy-5a-androstane; (5) 5alpha-androstan-3, 17-dione; (6) 3beta, 17beta-dihydroxy-5alpha-androst-1-ene; (7) 3alpha, 17beta-dihydroxy-5alpha-androst-1-ene; (8) 4-androstenediol; (9) 5-androstenediol; (10) 1-androstenedione; (11) 4-androstenedione; (12) 5-androstenedione; (13) Bolasterone; (14) Boldione; (15) Calusterone; (16) Desoxymethyltestosterone; (17) Delta 1-dihydrotestosterone; (18) 4-dihydrotestosterone; (19) Formebolone; (20) Methasterone; (21) 17alpha-methyl-3beta, 17beta-dihydroxy-5a-androstane; (22) 17alpha-methyl-3alpha, 17beta-dihydroxy-5a-androstane; (23) 17alpha-methyl-3beta, 17beta-dihydroxyandrost-4-ene; (24) 17alpha-methyl-4-hydroxynandrolone; (25) Methyldienolone; (26) Methyltrienolone; (27) 17alpha-methyl-delta 1-dihydrotestosterone; (28) 3beta, 17beta-dihydroxyestr-4-ene; (29) 3alpha, 17beta-dihydroxyestr-4-ene; (30) 3beta, 17beta-dihydroxyestr-5-ene; 	<p>3/17/2015 – signed by Governor.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Arizona</p> <p>2015 HB 2139 (Continued) (Page 4 of 4)</p>	<p>Adds the following substances to Schedule III:</p> <ul style="list-style-type: none"> (31) 3alpha, 17beta-dihydroxyestr-5-ene; (32) 19-nor-4,9(10)-androstenedione; (33) 19-nor-4-androstenedione; (34) 19-nor-5-androstenedione; (35) Norbolethone; (36) Norclostebol; (37) Normethandrolone; (38) Prostanazol; (39) Stenbolone; (40) Tetrahydrogestrinone; (41) Dronabinol, (synthetic delta-9-tetrahydrocannabinol) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product. <p>Adds the following substances to Schedule IV:</p> <ul style="list-style-type: none"> (1) Modafinil; (2) Sibutramine; (3) Alfaxalone (4) Fospropofol. (5) Suvorexant (6) Zopiclone (7) Lorcaseerin, <p>Adds the following substances to Schedule V:</p> <ul style="list-style-type: none"> (1) Ezogabine; (2) Lacosamide; (3) Pregabalin. 	<p>3/17/2015 – signed by Governor.</p>
<p>Arkansas</p>	<p>No pending proposed regulations. The state’s controlled substances list is published at AR ADC 007.07.001 and was last updated December 6, 2014.</p>	<p>N/A</p>

Yellow highlighted text indicates legislation that has been enacted into law.
Red text indicates that the legislature presently is not in session.
Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
California 2015 SB 139 (Page 1 of 10)	<p>Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances:</p> <p>(1) Adamantoylindoles or adamantoylindazoles, which includes adamantyl carboxamide indoles and adamantyl carboxamide indazoles, or any compound structurally derived from 3-(1-adamantoyl) indole, 3- (1-adamantoyl)indazole, 3-(2-adamantoyl)indole, N- (1-adamantyl)-1H-indole-3-carboxamide, or N- (1-adamantyl)-1H-indazole-3-carboxamide by substitution at the nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantyl ring to any extent, including, but not limited to, 2NE1, 5F-AKB-48, AB-001, AKB-48, AM-1248, JWH-018 adamantyl carboxamide, STS-135.</p> <p>(2) Benzoylindoles, which includes any compound structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including, but not limited to, AM-630, AM-661, AM-679, AM-694, AM-1241, AM-2233, RCS-4, WIN 48,098 (Pravadoline).</p>	2/5/2015 – referred to Committee on Public Safety.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
California 2015 SB 139 (Continued) (Page 2 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances: (3) Cyclohexylphenols, which includes any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the cyclohexyl ring to any extent, including, but not limited to, CP 47,497, CP 55,490, CP 55,940, CP 56,667, cannabicyclohexanol. (4) Cyclopropanoylindoles, which includes any compound structurally derived from 3-(cyclopropylmethanoyl)indole, 3-(cyclopropylmethanone)indole, 3-(cyclobutylmethanone)indole or 3-(cyclopentylmethanone)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cyclopropyl, cyclobutyl, or cyclopentyl rings to any extent.	2/5/2015 – referred to Committee on Public Safety.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
California 2015 SB 139 (Continued) (Page 3 of 10)	<p>Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances:</p> <p>(5) Naphthoylindoles, which includes any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl- (1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl,haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl group, 1-(N-methyl-2-pyrrolidinyl)methyl, 1- (N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the naphthyl ring to any extent, including, but not limited to AM-678, AM-1220, AM-1221, AM-1235, AM-2201, AM-2232, EAM-2201, JWH-004, JWH-007, JWH-009, JWH-011, JWH-015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-022, JWH-046, JWH-047, JWH-048, JWH-049, JWH-050, JWH-070, JWH-071, JWH-072, JWH-073, JWH-076, JWH-079, JWH-080, JWH-081,JWH-082, JWH-094, JWH-096, JWH-098, JWH-116, JWH-120, JWH-122, JWH-148, JWH-149, JWH-164, JWH-166, JWH-180, JWH-181, JWH-182, JWH-189, JWH-193, JWH-198, JWH-200, JWH-210, JWH-211, JWH-212, JWH-213, JWH-234, JWH-235, JWH-236, JWH-239, JWH-240, JWH-241, JWH-242, JWH-258, JWH-262, JWH-386, JWH-387, JWH-394, JWH-395, JWH-397, JWH-398, JWH-399, JWH-400, JWH-412, JWH-413, JWH-414, JWH-415, JWH-424, MAM-2201, WIN 55,212.</p> <p>(6) Naphthoynaphthalenes, which includes any compound structurally derived from naphthalene-1-yl-(naphthalene-1-yl) methanone with substitutions on either of the naphthalene rings to any extent, including, but not limited to, CB-13.</p>	2/5/2015 – referred to Committee on Public Safety.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
California 2015 SB 139 (Continued) (Page 4 of 10)	<p>Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances:</p> <p>(7) Naphthoylpyrroles, which includes any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including, but not limited to, JWH-030, JWH-031, JWH-145, JWH-146, JWH-147, JWH-150, JWH-156, JWH-243, JWH-244, JWH-245, JWH-246, JWH-292, JWH-293, JWH-307, JWH-308, JWH-309, JWH-346, JWH-348, JWH-363, JWH-364, JWH-365, JWH-367, JWH-368, JWH-369, JWH-370, JWH-371, JWH-373, JWH-392.</p> <p>(8) Naphthylmethylindenes, which includes any compound containing a naphthylideneindene structure or which is structurally derived from 1-(1-naphthylmethyl)indene with substitution at the 3-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including, but not limited to, JWH-171, JWH-176, JWH-220.</p>	2/5/2015 – referred to Committee on Public Safety.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
California 2015 SB 139 (Continued) (Page 5 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances (9) Naphthylmethylindoles, which includes any compound structurally derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2- (4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1- (N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including, but not limited to, JWH-175, JWH-184, JWH-185, JWH-192, JWH-194, JWH-195, JWH-196, JWH-197, JWH-199. (10) Phenylacetylindoles, which includes any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1- (N-methyl-2-pyrrolidinyl)methyl, 1- (N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including, but not limited to, cannabipiperidiethanone, JWH-167, JWH-201, JWH-202, JWH-203, JWH-204, JWH-205, JWH-206, JWH-207, JWH-208, JWH-209, JWH-237, JWH-248, JWH-249, JWH-250, JWH-251, JWH-253, JWH-302, JWH-303, JWH-304, JWH-305, JWH-306, JWH-311, JWH-312, JWH-313, JWH-314, JWH-315, JWH-316, RCS-8.	2/5/2015 – referred to Committee on Public Safety.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
California 2015 SB 139 (Continued) (Page 6 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances: (11) Quinolinyndolecarboxylates, which includes any compound structurally derived from quinolin-8-yl-1H-indole-3-carboxylate by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2- (4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the quinoline ring to any extent, including, but not limited to, BB-22, 5-Fluoro-PB-22, PB-22. (12) Tetramethylcyclopropanoylindoles, which includes any compound structurally derived from 3-tetramethylcyclopropanoylindole, 3- (1-tetramethylcyclopropyl)indole, 3- (2,2,3,3-tetramethylcyclopropyl)indole or 3- (2,2,3,3-tetramethylcyclopropylcarbonyl)indole with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl, 2-(4-morpholinyl)ethyl, 1- (N-methyl-2-pyrrolidiny)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropanoyl ring to any extent, including, but not limited to, 5-bromo-UR-144, 5-chloro-UR-144, 5-fluoro-UR-144, A-796,260, A-834,735, AB-034, UR-144, XLR11.	2/5/2015 – referred to Committee on Public Safety.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
California 2015 SB 139 (Continued) (Page 7 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances: (13) Tetramethylcyclopropane-thiazole carboxamides, which includes any compound structurally derived from 2,2,3,3-tetramethyl-N- (thiazol-2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent, including, but not limited to, A-836,339. (14) Unclassified synthetic cannabinoids, which includes all of the following: a. (A) AM-087, (6aR,10aR)-3- (2-methyl-6-bromohex-2-yl)-6,6,9-trimethyl-6 a,7,10,10a-tetrahydrobenzoc]chromen-1-ol; b. AM-356, Methanandamide, including (5Z,8Z,11Z,14Z)-N-(1R)-2-hydro xy-1-methylethyl]icosa-5,8,11,14-tetraenamide and arachidonyl-1?-hydroxy-2?-propylamide; c. AM-411, (6aR,10aR)-3- (1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-te trahydrobenzoc]chromen-1-ol; d. (D) AM-855, (4aR,12bR)-8-hexyl-2,5,5-trimethyl-1,4,4a,8,9,10,11,12b-o ctahydronaphtho3,2-c]isochromen-12-ol; e. (E) AM-905, (6aR,9R,10aR)-3-(E)-hept-1-enyl]-9-(hydroxymethyl)-6,6-d imethyl-6a,7,8,9,10,10a-hexahydrobenzoc]chromen-1-ol; f. AM-906, (6aR,9R,10aR)-3-(Z)-hept-1-enyl]-9-(hydroxymethyl)-6,6-d imethyl-6a,7,8,9,10,10a-hexahydrobenzoc]chromen-1-ol;	2/5/2015 – referred to Committee on Public Safety.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
California 2015 SB 139 (Continued) (Page 8 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances: <ul style="list-style-type: none"> g. AM-2389, (6aR,9R,10aR)-3- (1-hexyl-cyclobut-1-yl)-6a,7,8,9,10,10a- hexahydro-6,6-dimethyl-6H-dibenzob,d]pyran-1,9 diol; h. (H) BAY 38-7271, (-)-(R)-3- (2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4 -trifluorobutyl-1-sulfonate; i. CP 50,556-1, Levonantradol, including 9-hydroxy-6-methyl-3-5-phe nylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]ace etate; (6S,6aR,9R, 10aR)-9-hydroxy-6-methyl-3-(2R)-5-ph enylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; and 9-hydroxy-6-methyl-3-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10, 10a-octahydrophenanthridin-1-yl]acetate; j. HU-210, including (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- (2- methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzoc] chromen-1-ol; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyl octan-2-yl)-6a,7,10,10a-tetrahydrobenzoc]chromen-1-ol and 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol; k. HU-211, Dexanabinol, including (6aS, 10aS)-9-(hydroxymethyl)-6,6- dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzoc]chromen-1-ol and (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl- 3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzoc]chromen-1-ol; l. HU-243, 3-dimethylheptyl-11-hydroxyhexahydrocannabinol; m. HU-308, (91R,2R,5R)-2-2,6-dimethoxy-4- (2-methyloctan-2-yl)pheny l]-7,7-dimethyl-4-bicyclo3.1.1]hept-3-enyl]methanol; n. HU-331, 3-hydroxy-2-(1R,6R)-3-methyl-6- (1-methylethenyl)-2-cyclo hexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione; 	2/5/2015 – referred to Committee on Public Safety.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
California 2015 SB 139 (Continued) (Page 9 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances: <ul style="list-style-type: none"> o. HU-336, (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydr o-1H-benzoc]chromene-1,4(6H)-dione; p. JTE-907, N- (benzoc1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-penty loxy-1,2-dihydroquinoline-3-carboxamide; q. JWH-051, ((6aR,10aR)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzoc]chromen-9-yl)methanol; r. JWH-057 (6aR,10aR)-3- (1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro- 6,6,9-trimethyl-6H-Dibenzob,d]pyran; s. JWH-133 (6aR,10aR)-3- (1,1-Dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H-dibenzob,d]pyran; t. JWH-359, (6aR,10aR)- 1-methoxy- 6,6,9-trimethyl- 3-(2R)-1,1,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzoc]chromene; u. URB-597 3-(3-carbamoylphenyl)phenyl]-N-cyclohexylcarbamate; v. URB-602 1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester; OR cyclohexyl 1,1'-biphenyl]-3-ylcarbamate; w. URB-754 6-methyl-2- (4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one; x. URB-937 3'-carbamoyl-6-hydroxy-1,1'-biphenyl]-3-yl cyclohexylcarbamate; y. WIN 55,212-2, including (R)-(+)-2,3-dihydro-5-methyl-3-(4-morpho linylmethyl)pyrrolo1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethano one and 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo (1,2,3-de)-1,4-ben zoxazin-6-yl]-1-napthalenylmethanone. 	2/5/2015 – referred to Committee on Public Safety.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
California 2015 SB 139 (Continued) (Page 10 of 10)	Amends the definition of “synthetic stimulant compound” under state’s Controlled Substances Act to refer to the following substances: “Unless specifically excepted, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, or unless listed in another schedule, subdivisions (a) and (b) apply to any material, compound, mixture, or preparation which contains any quantity of a substance, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers whenever the existence of such salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers is possible, that is structurally derived from 2-amino-1-phenyl-1-propanone by modification in one of the following ways: (1) By substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents. (2) By substitution at the 3-position with an alkyl substituent. (3) By substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.	2/5/2015 – referred to Committee on Public Safety.
Colorado	No pending proposed legislation.	
Connecticut	No pending proposed regulations. The regulations were last updated in September 2013.	
Delaware	No pending proposed legislation.	

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
District of Columbia 2015 LB 23	The legislation is the “Marijuana Legalization and Regulation Act of 2015.” Among many other things, it provides that hashish is a Schedule II controlled substance “only as it relates to D.C. Official Code § 50-2206.01 for the purpose of defining controlled substances as they relate only to driving under the influence of drugs.” Also provides that cannabis is a Schedule III controlled substance “only when it relates to . . . [d]riving or boating under the influence of drugs pursuant to D.C. Official Code § 50-2206.01.”	2/9/2015 – public hearing.
Florida 2015 HB 287	Adds Kratom (<i>mitragyna speciosa</i>) to Schedule I.	3/3/2015 – introduced.
Florida 2015 HB 897	Adds the following substances to Schedule I: <ul style="list-style-type: none"> (1) AB-CHMINACA: N-[1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; (2) FUB-PB-22: Quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate; (3) Fluoro-NNEI: 1-(Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide; (4) Fluoro-AMB: Methyl 2-(1-(fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate; (5) 180. THJ-2201: [1-(5-Fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone. 	3/13/2015 – substituted bill referred to Justice Appropriations Committee.
Florida 2015 HB 4041	Removes cannabis from schedule of controlled substances.	3/3/2015 – introduced; referred to Criminal Justice Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Florida 2015 SB 764	Adds “Mitragynine or 7-Hydroxymitragynine, except for any drug product approved by the United States Food and Drug Administration which contains Mitragynine or 7 Hydroxymitragynine, including any of their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, if the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation” to Schedule I.	3/17/2015 – committee substitute bill read first time.
Florida 2015 SB 1098	Adds the following substances to Schedule I: (1) AB-CHMINACA: N-[1-(aminocarbonyl)-2-methylpropyl]-1 (cyclohexylmethyl)-1H-indazole-3-carboxamide; (2) FUB-PB-22: Quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole 3-carboxylate; (3) Fluoro-NNEI: 1-(Fluoropentyl)-N-(naphthalen-1-yl)-1H indole-3-carboxamide; (4) 5-Fluoro-AMB: Methyl 2-(1-(fluoropentyl)-1H-indazole 3-carboxamido)-3-methylbutanoate; (5) [1-(5-Fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone.	3/3/2015 – introduced.
Florida 2015 SB 1294	Removes cannabis from schedule of controlled substances.	3/3/2015 – introduced.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Georgia 2015 HB 211	<p>Adds the following substances to Schedule I:</p> <ol style="list-style-type: none"> (1) 3-(1,3-benzenodioxol-5-yl)-N,2-dimethylpropan-1-amine (3,4-methylenedioxymethamphetamine methyl homolog); (2) (2-aminopropyl)-2,3-dihydrobenzofuran (APDB); (3) 4-methyl-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25D-NBOMe); (4) 2-chloro-4,5-methylenedioxymethamphetamine; (5) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); (6) 2-bromo-4,5-methylenedioxymethamphetamine; (7) 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25H-NBOMe); (8) Naphthalene-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201); (9) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (FUB-144); (10) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-fluoro-ABICA); (11) 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone (THJ 018). <p>Removes the following combination products from Schedule III:</p> <ol style="list-style-type: none"> (1) Not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; (2) Not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. <p>Adds the following substances to Schedule IV:</p> <ol style="list-style-type: none"> (1) Alfaxalone; (2) Etizolam; (3) Phenazepam; (4) Suvorexant. 	3/18/2015 – passed by Senate.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Hawaii 2015 HB 331	Adds nicotine to the substances listed in Schedule V.	1/26/2015 – introduced and referred to Committees on Judiciary and Health.
Hawaii 2015 HB 841	Among other things, removes the following from Schedule I: (1) Marijuana; (2) Tetrahydrocannabinols.	1/28/2015 – introduced and referred to Committees on Judiciary and Health.
Hawaii 2015 HB 889	Among other things, removes the following from Schedule I: (1) Marijuana; (2) Tetrahydrocannabinols.	1/28/2015 – introduced and referred to Committees on Judiciary and Health.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Hawaii 2015 HB 962	<p>Removes the following combination products from Schedule III:</p> <ul style="list-style-type: none"> (1) Not more than 300 milligrams of dihydrocodeinone (Hydrocedene), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium provided that these narcotic drugs shall be monitored pursuant to section 329-101; (2) Not more than 300 milligrams of dihydrocodeinone (Hydrocodone), or any of its salts per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognised therapeutic amounts provided that these narcotic drugs shall be monitored pursuant to section 329-101; <p>Adds the following to Schedule IV.</p> <ul style="list-style-type: none"> (1) Suvorexant; (2) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 	1/29/2015 – introduced and referred to Committees on Judiciary and Health.
Hawaii 2015 SB 189	Removes marijuana and its intrinsic cannabinoids from Schedule I and requires the state Department of Public Safety, in consultation with the state Department of Health, to issue a recommendation for the rescheduling of marijuana.	2/26/2015 – Measure deferred by Committee on Judiciary and Labor.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Hawaii 2015 SB 383	Among other things, removes the following from Schedule I: (1) Marijuana; (2) Tetrahydrocannabinols.	1/26/2015 – Referred to House Committee on Public Safety and Military Affairs; referred to Senate Committees on Judiciary and Labor and Ways and Means.
Hawaii 2015 SB 1131 (Page 1 of 2)	Adds the following substances to Schedule I: (1) 1-(benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one, monohydrochloride, also known as Ethylone, bk-MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-ethylcathinone; bk-Methylenedioxyethylamphetamine; (2) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: AB-CHMINACA); (3) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, and geometric isomers, salts, and salts of isomers (Other names: AB-PINACA); (4) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone, and geometric isomers, salts, and salts of isomers (Other names: THJ-2201); (5) Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate, and geometric isomers, salts, and salts of isomers (other names: FUB-AMB);	3/12/2015 – referred to House Health and Judiciary Committees.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Hawaii</p> <p>2015 SB 1131 (Continued) (Page 2 of 2)</p>	<p>Adds the following substances to Schedule I:</p> <ul style="list-style-type: none"> (6) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, and geometric isomers, salts, and salts of isomers (Other names: 5-fluoro-AMB, 5-fluoro-AMP); (7) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, and geometric isomers, salts, and salts of isomers (Other names: AKB48 N-(5-fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl analog, 5F-APINACA); (8) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and geometric isomers, salts, and salts of isomers (Other names: STS-135, 5F-APICA; 5-fluoro-APICA); (9) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, and geometric isomers, salts, and salts of isomers (Other names: NM2201). <p>Removes the following combination products from Schedule III:</p> <ul style="list-style-type: none"> (1) Not more than 300 milligrams of dihydrocodeinone (Hydrocedene), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium provided that these narcotic drugs shall be monitored pursuant to section 329-101; (2) Not more than 300 milligrams of dihydrocodeinone (Hydrocodone), or any of its salts per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognised therapeutic amounts provided that these narcotic drugs shall be monitored pursuant to section 329-101; <p>Adds the following to Schedule IV.</p> <ul style="list-style-type: none"> (1) Suvorexant; (2) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 	<p>3/12/2015 – referred to House Health and Judiciary Committees.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Idaho	No pending proposed legislation.	
Illinois 2015 HB 1497	Adds alpha-Pyrrolidinopentiophenone to Schedule I.	3/5/2015 – Referred to Committee on Sentencing, Penalties, and Criminal Procedure.
Illinois 2015 HB 3588	Adds provision to Schedule I that “if the Department [of Human Services] adopts an emergency rule under Section 10 of the Synthetic Drug Identification Pilot Program Act adding a synthetic drug to the list of Schedule I controlled substances that drug shall be automatically added as a Schedule I controlled substance upon the effective date of the emergency rule.”	3/18/2015 – Committee amendment referred to Rules Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Illinois 2015 SB 1282 (Page 1 of 4)	Adds the following substances to Schedule I: Synthetic cannabinoids or piperazines. Unless specifically excepted, any chemical compound which is not approved by the United States Food and Drug Administration or, if approved, which is not dispensed or possessed in accordance with State and federal law, that contains: <ol style="list-style-type: none"> (1) Benzylpiperazine (BZP); (2) Trifluoromethylphenylpiperazine (TFMPP); (3) 1,1- Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-naphthoyl) indole; 1-Pentyl-3-(1-naphthoyl) indole; (4) dexanabinol (HU-211); or (5) any compound in the following structural classes: <ol style="list-style-type: none"> a. Naphthylmethylinoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-175, JWH-184, and JWH-185; b. Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-167, JWH-250, JWH-251, and RCS-8; 	2/25/2015 – assigned to Criminal Law Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Illinois 2015 SB 1282 (Continued) (Page 2 of 4)	Adds the following substances to Schedule I: <ul style="list-style-type: none"> c. Benzoylindoles: Any compound containing a 3-(benzoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of this structural class include, but are not limited, to AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; d. Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural class include, but are not limited to, CP 47,497 and its C8 homologue (cannabicyclohexanol); e. Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-175, JWH-184, and JWH-185; f. Naphthoypyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited, to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368 	2/25/2015 – assigned to Criminal Law Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Illinois 2015 SB 1282 (Continued) (Page 3 of 4)	<p>Adds the following substances to Schedule I:</p> <ul style="list-style-type: none"> g. Naphthylmethylindenes: Any compound containing a 1-(1-naphthylmethyl)indene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-176; h. Any other synthetic cannabinoid or piperazine which is not approved by the United States Food and Drug Administration or, if approved, which is not dispensed or possessed in accordance with State and federal law. <p>Synthetic cathinones. Unless specifically excepted, any chemical compound which is not approved by the United States Food and Drug Administration or, if approved, which is not dispensed or possessed in accordance with State and federal law, not including bupropion, structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in one or more of the following ways:</p> <ul style="list-style-type: none"> (1) By substitution in the ring system to any extent with alkyl, alkylendioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents. Examples of this class include, but are not limited to, 3,4-Methylenedioxcathinone (bk-MDA); 	2/25/2015 – assigned to Criminal Law Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Illinois 2015 SB 1282 (Continued) (Page 4 of 4)	Adds the following substances to Schedule I: (2) By substitution at the 3-position with an acyclic alkyl substituent. Examples of this class include, but are not limited to, 2-methylamino-1-phenylbutan-1-one (buphedrone); (3) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. Examples of this class include, but are not limited to, Dimethylcathinone, Ethcathinone, and a-Pyrrolidinopropiophenone (a-PPP); (4) Any other synthetic cathinone which is not approved by the United States Food and Drug Administration or, if approved, is not dispensed or possessed in accordance with State or federal law.	2/25/2015 – assigned to Criminal Law Committee.
Indiana 2015 HB 1184	Removes the following combination products from Schedule III: (1) Not more than 300 milligrams of dihydrocodeinone, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium. (2) Not more than 300 milligrams of dihydrocodeinone, per 100 milliliters or not more than 15 milligrams per dosage unit, with one (1) or more active nonnarcotic ingredients in recognized therapeutic amounts. Adds Tramadol (Ultram) to Schedule IV.	3/23/2015 – enrolled.
Indiana 2015 HB 1382	Adds Ephedrine and Pseudoephedrine to Schedule III.	1/14/2015 – first reading; referred to Committee on Public Health.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Indiana 2015 HB 1562	Adds hydrocodone combination products to Schedule II. Adds Tramadol to Schedule IV.	3/2/2015 – First reading in Senate; referred to Committee on Commerce & Technology.
Indiana 2015 HB 1602	Among other things, adds Ephedrine and Pseudoephedrine to Schedule IV.	1/20/2015 – first reading and referred to Committee on Courts and Criminal Code.
Indiana 2015 SB 290	Adds Ephedrine and Pseudoephedrine to Schedule III.	1/8/2015 – first reading and referred to Committee on Corrections & Criminal Law.
Indiana 2015 SB 445	Adds the following provision to Schedule IV: This subsection applies from July 1, 2015, through June 30, 2018. Except for a product that has been found by the Indiana board of pharmacy to be an extraction resistant or conversion resistant form of ephedrine or pseudoephedrine under IC 25-26-13-4.2, a material, compound, mixture, or preparation that contains a quantity of any of the following substances, pure or adulterated: (1) Ephedrine. (2) Pseudoephedrine.	1/14/2015 – reassigned to Committee on Corrections & Criminal Law.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Indiana 2015 SB 536	Adds the following provision to Schedule IV: “This subsection applies from July 1, 2020, through June 30, 2023, unless the superintendent of the state police department has submitted a report under IC 10-11-2-34 showing that four hundred (400) or fewer methamphetamine laboratories were discovered in Indiana during calendar year 2019. Except for a product that has been found by the Indiana board of pharmacy to be an extraction resistant or conversion resistant form of ephedrine or pseudoephedrine under IC 25-26-13-4.2, a material, compound, mixture, or preparation that contains a quantity of any of the following substances, pure or adulterated: (1) Ephedrine. (2) Pseudoephedrine.” .	3/5/2015 – first reading in House; referred to Committee on Courts and Criminal Code.
Iowa 2015 HF 567 (Page 1 of 4)	Adds the following substances to Schedule I: (1) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D); (2) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); (3) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); (4) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2); (5) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4); (6) 2-(2,5-Dimethoxyphenyl) ethanamine (2C-H); (7) 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C-N); (8) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); (9) HU-210. [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 6a,7,10,10a20 tetrahydrobenzo[c] chromen-1-ol)]; (10) HU-211(dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol).	3/17/2015 – read first time in Senate; referred to Judiciary Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Iowa</p> <p>2015 HF 567 (Continued) (Page 2 of 4)</p>	<p>Adds the following new paragraph to Schedule I:</p> <p>“Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.</p> <p>(1) The term "cannabimimetic agents" means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:</p> <ol style="list-style-type: none"> a. 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent. b. 3-(1-naphthoyl)indole or 3-(1-naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent. c. 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent. d. 1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent. e. 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent. 	<p>3/17/2015 – read first time in Senate; referred to Judiciary Committee.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Iowa 2015 HF 567 (Continued) (Page 3 of 4)	<p>(2) Such terms include:</p> <ul style="list-style-type: none"> a. (a) CP 47,497 and homologues 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]phenol; b. JWH-018 and AM678 1-Pentyl-3-(1-naphthoyl)indole; c. JWH-073 1-Butyl-3-(1-naphthoyl)indole; d. JWH-200[1-[2-(4-morpholinyl)ethyl]-1H26 indol-3-yl]-1-naphthalenyl-methanone; e. JWH-19 1-hexyl-3-(1-naphthoyl)indole; f. JWH-81 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole; g. JWH-122 1-pentyl-3-(4-methyl-1-naphthoyl)indole; h. JWH-250 1-pentyl-3-(2-methoxyphenylacetyl)indole; i. RCS-4 and SR-19 1-pentyl-3-[(4methoxy)-benzoyl]indole; j. RCS-8 and SR 18 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole; k. AM2201 1-(5-fluoropentyl)-3-(1-naphthoyl)indole; l. JWH-203 1-pentyl-3-(2-chlorophenylacetyl)indole; m. JWH-398 1-pentyl-3-(4-chloro-1-naphthoyl)indole; n. AM694 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; o. Cannabicyclohexanol or CP-47,497 C8-homolog 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol. <p>Adds the following substances to Schedule I:</p> <ul style="list-style-type: none"> (1) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4- fluorobenzyl)-1H-indazole-3-carboxamide. Other names: AB-FUBINACA; (2) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1 H-indazole-3-carboxamide. Other names: ADB-PINACA; (3) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate. Other names: PB-22, QUPIC; (4) Quinolin-8-yl 1-(5-fluoropentyl)- 1H-indole-3-carboxylate. Other names: 5-fluoro-PB-22, 5F-PB-22; (5) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide. Other names: AB-PINACA; (6) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide. Other names: AB-CHMINACA; (7) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone. Other names: THJ-2201. 	3/17/2015 – read first time in Senate; referred to Judiciary Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Iowa 2015 HF 567 (Continued) (Page 4 of 4)	Adds the following to Schedule III: 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers, and salts of these isomers (including tramadol). Adds Alfaxalone and Suvorexant to Schedule IV.	3/17/2015 – read first time in Senate; referred to Judiciary Committee.
Iowa 2015 SF 282	Moves marijuana, including tetrahydrocannabinols, from Schedule I to Schedule II.	2/19/2015 – introduced; referred to Human Resources Committee.
Kansas 2015 HB 2275 (Page 1 of 2)	Adds the following substances to Schedule I: <ul style="list-style-type: none"> (1) 2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl) ethanamine Some trade or other names: 25D-NBOMe; 2C-D-NBOMe; (2) (1H-indazol-3-yl)methanones. Any compound containing a (1H-indazol-3-yl)methanone structure with the carbonyl carbon bearing a naphthyl group and substitution at the 1 position of the indazole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted on the indazole ring to any extent and whether or not substituted on the naphthyl or benzyl groups to any extent. Moves the following combination product from Schedule III to Schedule II: <ul style="list-style-type: none"> (1) (1) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) or any of its salts per 100 milliliters or not more than 15 milligrams per dosage unit with a fourfold or greater quantity of an isoquinoline alkaloid of opium 	3/19/2015 – Senate committee report recommending measure be passed.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Kansas 2015 HB 2275 (Continued) (Page 2 of 2)	Moves the following combination product from Schedule III to Schedule II: <p>(2) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) or any of its salts per 100 milliliters or not more than 15 milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.</p> <p>Adds Perampanel, its salts, isomers, and salts of isomers [Some other names for perampanel: 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile] to Schedule III.</p> <p>Adds the following substances to Schedule IV: <p>(1) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol)</p> <p>(2) Alfaxalone</p> <p>(3) Suvorexant.</p></p>	3/19/2015 – Senate committee report recommending measure be passed.
Kentucky 2015 HB 32	Adds Acetylfentanyl to Schedule I.	1/6/2015 – introduced.
Kentucky 2015 HB 51	Adds the following substance to Schedule I: “Any extended release single-agent formulation of hydrocodone bitartrate that does not contain tamper-resistant or tamper-deterrent countermeasures as approved by the federal Food and Drug Administration.”	1/6/2015 – introduced.
Kentucky 2015 HB 53	Adds the following substance to Schedule I: “Any extended release single-agent formulation of hydrocodone bitartrate, including the drug Zohydro, that does not contain tamper-resistant or tamper-deterrent countermeasures as approved by the federal Food and Drug Administration.”	1/6/2015 – introduced.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Kentucky 2015 HB 213	Among other provisions, adds Acetylfentanyl to Schedule I.	2/20/2015 – referred to Senate Judiciary Committee.
Kentucky 2015 HB 192	Among other provisions, adds Acetylfentanyl to Schedule I.	3/11/2015 – passed House.
Louisiana 2015 HB 72 (Page 1 of 2)	Adds the following substances to Schedule I: (1) 4-bromo-2,5-dimethoxyphenethylamine (2C-B); (2) N-(2-methoxybenzyl)-2,5-dimethoxy-4-bromophenethylamine (25B-NBOMe); (3) (2-methylaminopropyl)benzofuran (5-MAPB); (4) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-Hydroxy-MIPT); (5) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)butan-1-one (Alpha-PBT) (6) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)pentan-1-one (Alpha-PVT); (7) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate; (8) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; (9) N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide; (10) naphthalen-1-yl-1-pentyl-1H-indazole-3-carboxylate; (11) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; (12) 1-(5-fluoropentyl)N-naphthalen-1-yl-1H-pyrrolo[3,2-c]pyridine-3-carboxamide; (13) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3-methyl-butanoate; (14) methyl 2-(1-pentyl-1H-indazole-3-carboxamido)-3-methylbutanoate; (15) 1-(5-fluoropentyl)-N-(quinolin-8-yl)-1H-indole-3-carboxamide;	3/9/2015 – prefiled.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Louisiana 2015 HB 72 (Continued) (Page 2 of 2)	Adds the following substances to Schedule I: (1) N-fenchyl-1-[2-(morpholin-4-yl)ethyl]-7-methoxyindole-3-carboxamide; (2) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; (3) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate; (4) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; (5) naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl) methanone.	3/9/2015 – prefiled.
Maine 2015 SP 259	Adds Acetylfentanyl to the list of Schedule W drugs.	3/10/2015 – referred to the Committee on Criminal Justice & Public Safety.
Maryland 2015 HB 1057	Adds the following definition to the state’s controlled substance laws: “‘synthetic cannabinoid’ means substances that bind to the cannabinoid receptor or mimic the pharmacological response of a controlled dangerous substance listed in schedule i or schedule ii. “‘Synthetic cannabinoid’ does not include any drug that has been approved by the federal food and drug administration.” Adds “synthetic cannabinoid” to the list of substances in Schedule I.	3/15/2015 – second reading passed with amendments.
Massachusetts 2015 HB 1155	Adds the following substances to Class B: (1) , 2-(4-iodo-2 ,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5); (2) 2-(4-chloro-2 ,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82), (3) 2-(4-bromo-2 ,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36).	3/10/2015 – referred to Joint Committee on Judiciary.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Massachusetts 2015 HB 1478	<p>Adds the following substances to Class C:</p> <p>Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any Cannabimimetic Agents that meet the criteria of any one or more of paragraphs (a) through (e) and any substance within the structural classes identified below that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays:</p> <ol style="list-style-type: none"> (1) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent; (2) 3-(1-naphthoyl)indole or 3-(1-naphthyl)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent; (3) 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the naphthoyl ring to any extent; (4) 1-(1-naphthylmethyl)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent; (5) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent. 	3/10/2015 – referred to Joint Committee on Judiciary.
Massachusetts 2015 HB 1561	Among many other provisions, removes marijuana from Class D.	3/10/2015 – referred to Joint Committee on Judiciary.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Massachusetts 2015 HB 1791	Adds oxycodone to Class A.	3/11/2015 – referred to Joint Committee on Mental Health and Substance Abuse.
Michigan	No pending proposed legislation.	
Minnesota 2015 HF 1376 (Page 1 of 3)	Adds the following substances to Schedule I: (1) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe); (2) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe); (3) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) . ; (4) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); (5) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2); (6) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP); (7) 4-methyl-N-ethylcathinone (4-MEC); (8) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP); (9) 2-(methylamino)-1-phenylpentan-1-one (pentedrone); (10) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone); (11) 4-fluoro-N-methylcathinone (4-FMC); (12) 3,4-methylenedioxy-N-ethylcathinone (ethylone); (13) alpha-pyrrolidinobutiophenone (α-PBP); (14) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB); (15) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB); (16) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide(AB-CHMINACA); (17) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3- methylbutanoate (5-fluoro-AMB);	3/2/2015 – introduced and referred to Committee on Public Safety and Crime Prevention Policy and Finance.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Minnesota 2015 HF 1376 (Continued) (Page 2 of 3)	<p>Adds the following substances to Schedule I:</p> <ul style="list-style-type: none"> (18) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201); (19) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone (FUBIMINA); (20) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12); (21) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl) -1H-indole-3-carboxamide (5-fluoro-ABICA); (22) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) -1H-indole-3-carboxamide; (23) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) -1H-indazole-3-carboxamide; (24) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-dimethylbutanoate. <p>Adds the following substances to Schedule II:</p> <ul style="list-style-type: none"> (1) naloxegol; (2) 4-Anilino-N-phenethyl-4-piperidine (ANPP); <p>Adds the following substances to Schedule III:</p> <ul style="list-style-type: none"> (1) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-Dihydropyridin-3-yl) benzonitrile]; (2) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-androstan-17beta-ol-3-one); (3) prostanazol (17 beta-hydroxy-5 alpha-androstano[3,2-C]pyrazole); (4) Chorionic gonadotropin. 	3/2/2015 – introduced and referred to Committee on Public Safety and Crime Prevention Policy and Finance.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Minnesota 2015 HF 1376 (Continued) (Page 3 of 3)	<p>Removes the following combination products from Schedule III:</p> <ul style="list-style-type: none"> (1) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; (2) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. <p>Adds the following substances to Schedule IV:</p> <ul style="list-style-type: none"> (1) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers, and salts of these isomers (including tramadol); (2) Alfaxalone (5-β-pregnan-3α-ol-11,20-dione); (3) fospropofol; (4) nordiazepam; (5) petrichloral; (6) Suvorexant; (7) lorcaserin. <p>Adds ezogabine to Schedule V.</p>	3/2/2015 – introduced and referred to Committee on Public Safety and Crime Prevention Policy and Finance.
Minnesota 2015 SF 1219	Companion bill to 2015 HF 1376.	3/16/2015 – committee report: pass.
Mississippi 2015 HB 241	Adds “derivatives of synthetic cannabinoids” to Schedule I.	2/3/2015 – died in committee.
Mississippi 2015 HB 562	Removes “industrial hemp as regulated in Sections 1 through 3 of House Bill No. , 2015 Regular Session” from the definition of Tetrahydrocannabinols.	2/3/2015 – died in committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Mississippi</p> <p>2015 HB 1332</p>	<p>Adds the following substances to Schedule I:</p> <p>Synthetic cathinones unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cothinone found in any of the following compounds, whether or not substituted to any extent, or any of those compounds which contain any synthetic cothinone salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible:</p> <ul style="list-style-type: none"> (1) 4-methyl-N-ethylcathinone ("4-MEC"); (2) 4-methyl-alpha-pyrrolidinopropiophenone ("4-MePPP"); (3) alpha-pyrrolidinopentiophenone ("a-PVP"); (4) 1-(1,3-vebziduijik-5-yl)-2-(methylamino)butan-1-one ("butylone); (5) 2-(methylamino)-1-phenylpentan-1-one ("pentedrone"); (6) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one ("pentylone"); (7) 4-fluoro-N-methylcathinone ("4-FMC"); (8) 3-fluoro-N-methylcathinone ("3-FMC"); (9) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one("naphyrone"); (10) alpha-pyrrolidinobutiophenone("a-PBP"). <p>Adds Perampanel to Schedule III.</p> <p>Removes the following combination products from Schedule III:</p> <ul style="list-style-type: none"> (1) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; (2) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. <p>Adds Alfaxalone to Schedule IV.</p>	<p>2/3/2015 – died in committee.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Mississippi 2015 SB 2118	Similar to 2015 HB 1332.	3/18/2015 – Senate declined to concur w/ House amendments.
Mississippi 2015 SB 2318	Moves marijuana, hashish and Tetrahydrocannabinols from Schedule I to Schedule II.	2/3/2015 – died in committee.
Missouri 2015 HB 701	Exempts industrial hemp from definition of marijuana in Schedule I.	2/10/2015 – referred to Emerging Issues Committee.
Missouri 2015 HB 830	Exempts industrial hemp from definition of marijuana in Schedule I.	3/18/2015 – House committee report: do pass as substituted.
Missouri 2015 HB 930	Among many other provisions, moves marijuana from Schedule I to Schedule II.	2/24/2015 – referred to Emerging Issues Committee.
Missouri 2015 HB 1170	Adds provision that “beginning January 1, 2017, the director of the department of health and senior services shall notify the revisor of statutes of any controlled substances that are added or removed from the five schedules of controlled substances established by the federal Controlled Substances Act under 21 U.S.C. section 801, et seq. The revisor shall change the statutory schedule of controlled substances listed in this section to include such additions or deletions.”	3/19/2015 – referred to Public Safety and Emergency Preparedness Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Missouri 2015 SB 255	Among many other provisions, the bill exempts industrial hemp, which is defined as cannabis sativa L. containing no greater than 3/10 of one percent THC, from the definition of marijuana and the list of controlled substances.	3/4/2015 – committee hearing conducted.
Montana	No pending proposed legislation.	
Nebraska 2015 LB 189	Adds marijuana concentrate to Schedule I. Removes hashish, concentrated cannabis, and Tetrahydrocannabinols from Schedule I. Changes the definition of Synthetic Tetrahydrocannabinols in Schedule I to: “Any equivalent of the substances naturally contained in a plant of the genus cannabis or derivatives and their isomers with similar chemical structure and pharmacological activity. Synthetic tetrahydrocannabinols includes the following: Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans tetrahydrocannabinol, and its optical isomers. Synthetic tetrahydrocannabinols does not include dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the federal Food and Drug Administration.”	2/20/2015 – Judiciary Committee amendment filed.
Nebraska 2015 LB 326 (Page 1 of 2)	Removes entry for “hashish or concentrated cannabis” from Schedule I. Revises descriptions of synthetically produced cannabinoids in Schedule I. Adds the following substances to Schedule II: <ul style="list-style-type: none"> (1) Lisdexamfetamine; (2) Immediate precursor to fentanyl; 4-anilino-N-phenethyl-4-piperidine (ANNPP). Adds the following substances to Schedule III: <ul style="list-style-type: none"> (1) Embutramide; (2) Perampanel; 	2/6/2015 – notice of hearing for 3/6/2015.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Nebraska 2015 LB 326 (Continued) (Page 1 of 2)	<p>Makes numerous revisions to the listing of anabolic steroids in Schedule III.</p> <p>Removes the following combination products from Schedule III:</p> <ul style="list-style-type: none"> (1) Not more than three hundred milligrams of dihydrocodeinone which is also known as hydrocodone per one hundred milliliters or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; (2) Not more than three hundred milligrams of dihydrocodeinone which is also known as hydrocodone per one hundred milliliters or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. <p>Adds the following substances to Schedule IV:</p> <ul style="list-style-type: none"> (1) Zopiclone; (2) Fospropofol; (3) Alfaxalone; (4) Suvorexant; (5) Carisoprodol; (6) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers to include: Tramadol; (7) Butorphanol; (8) Lorcaseerin. 	2/6/2015 – notice of hearing for 3/6/2015.
Nevada 2015 SB 234	<p>Requires the state Board of Pharmacy to designate, by extraordinary regulation, salvia divinorum and certain substances commonly known as synthetic marijuana in the list of schedule I controlled substances.</p>	3/9/2015 – read first time and referred to Committee on Health and Human Services.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>New Hampshire</p> <p>2015 SB 106 (Page 1 of 9)</p>	<p>New Hampshire does not publish a state list of controlled substances, instead relying on the federal schedules. This legislation makes it illegal to sell or distribute “any substance containing a synthetic drug,” noting that the drugs classified as “synthetic drugs” are not all on the federal controlled substance schedules.</p> <p>The definition of “synthetic drug” is:</p> <ol style="list-style-type: none"> (1) Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with a substituent at the 5-position of the phenolic ring: whether or not substituted on the cyclohexyl ring to any extent;d (2) Any compound containing a 1-(1-naphthylmethyl)indene ring system with a substituent at the 3-position of the indene ring system: whether or not further substituted on the indene ring to any extent, and whether or not substituted on the naphthyl ring to any extent; (3) Any compound containing an indole ring system with a substituent on the nitrogen atom and bearing an additional substituent at the 3-position of the indole ring system, with a linkage connecting the ring system to the substituent: <ol style="list-style-type: none"> a. Where the linkage connecting the indole ring system to the substituent at its 3-position is any of the following: (A) Alkyl, (B) Carbonyl, (C) Ester, (D) Thione, (E) Thioester, (F) Amino, (G) Alkylamino, (H) Amido, (I) Alkylamido. b. Where the substituent at the 3-position of the indole ring system is, disregarding the linkage, any of the following groups: (A) Naphthyl, (B) Quinoliny, (C) Adamantyl, (D) Phenyl,(E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), (F) Biphenyl, (G) Allcylamido (limited to ethylamido, propylamido, butanamido, or pentanamido), (H) Benzyl, (I) Carboxylic acid, (J) Ester, (K) Ether, (L) Phenylpropylamido, (M) Phenylpropylamino. 	<p>3/4/2015 – introduced in House and referred to Committee on Criminal Justice and Public Safety.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 2 of 9)</p>	<p>c. Whether or not the substituent at the 3-position of the indole ring system, disregarding the linkage, is further substituted to any extent.</p> <p>d. Whether or not further substituted on the indole ring system to any extent.</p> <p>(4) Any compound containing an indazole ring system with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the indazole ring system, with a linkage connecting the ring system to the substituent:</p> <p>a. Where the linkage connecting the indazole ring system to the substituent at its 3-position is any of the following: (A) Alkyl.(B) Carbonyl.(C) Ester.(D) Thione.(E) Thioester. (F) Amino.(G) Alkylamino.(H) Amido.(I) Alkylamido.</p> <p>b. Where the substituent at the 3-position of the indazole ring system is, disregarding the linkage, any of the following groups: (A) Naphthyl.(B) Quinolinylnyl.(C) Adamantyl.(D) Phenyl. (E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).(F) Biphenyl.(G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).(H) Benzyl.(I) Carboxylic acid.(J) Ester.(K) Ether.(L) Phenylpropylamido.(M) Phenylopropylamino.</p> <p>c. Whether or not the substituent at the 3-position of the indazole ring system, disregarding the linkage, is further substituted to any extent.</p> <p>d. Whether or not further substituted on the indazole ring system to any extent.</p>	<p>3/4/2015 – introduced in House and referred to Committee on Criminal Justice and Public Safety.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 3 of 9)</p>	<p>(5) Any compound containing a pyrrole ring with a substituent on the nitrogen atom and bearing an additional substituent at the 3-position of the pyrrole ring, with a linkage connecting the ring to the substituent:</p> <p>a. Where the linkage connecting the pyrrole ring to the substituent at its 3-position is any of the following: (A) Alkyl.(B) Carbonyl.(C) Ester.(D) Thione.(E) Thioester.(F) Amino.(G) Alkylamino.(H) Amido.(I) Alkylamido.</p> <p>b. Where the substituent at the 3-position of the pyrrole ring is, disregarding the linkage, any of the following groups: (A) Naphthyl.(B) Quinolinylnyl.(C) Adamantyl.(D) Phenyl.(E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).(F) Biphenyl.(G) Alkylamido (limited to ethylamido, propylamido, butylamido, or pentylamido).(H) Benzyl.(I) Carboxylic acid.(J) Ester.(K) Ether.(L) Phenylpropylamido. (M) Phenylpropylamino.</p> <p>c. Whether or not the substituent at the 3-position of the pyrrole ring, disregarding the linkage, is further substituted to any extent.</p> <p>d. Whether or not further substituted on the pyrrole ring to any extent.</p> <p>(6) Any compound containing a pyrazole ring with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the pyrazole ring with a linkage connecting the ring to the substituent:</p> <p>a. Where the linkage connecting the pyrazole ring to the substituent at its 3-position is any of the following: (A) Alkyl.(B) Carbonyl.(C) Ester.(D) Thione.(E) Thioester.(F) Amino.(G) Alkylamino.(H) Amido.(I) Alkylamido.</p> <p>b. Where the substituent at the 3-position of the pyrazole ring is, disregarding the linkage, any of the following groups:</p>	<p>3/4/2015 – introduced in House and referred to Committee on Criminal Justice and Public Safety.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 4 of 9)</p>	<p>(A) Naphthyl.(B) Quinolinylnyl.(C) Adamantyl.(D) Phenyl.(E) Cyclopentyl, or cyclohexyl.(F) Cycloalkyl (limited to cyclopropyl, cyclobutyl, or biphenyl).(G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).(H) Benzyl.(I) Carboxylic acid.(J) Ester.(K) Ether.(L) Phenylpropylamido. (M) Phenylpropylamino.</p> <p>c. Whether or not the substituent at the 3-position of the pyrazole ring, disregarding the linkage, is further substituted to any extent.</p> <p>d. Whether or not further substituted on the pyrazole ring to any extent.</p> <p>(7) Any compound containing a pyrazole ring with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the pyrazole ring with a linkage connecting the ring to the substituent:</p> <p>a. Where the linkage connecting the pyrazole ring to the substituent at its 3 position is any of the following: (A) Alkyl.(B) Carbonyl.(C) Ester.(D) Thione.(E) Thioester.(F) Amino.(G) Alkylamino.(H) Amido.(I) Alkylamido.</p> <p>b. Where the substituent at the 3 position of the pyrazole ring is, disregarding the linkage, any of the following groups: (A) Naphthyl.(B) Quinolinylnyl.(C) Adamantyl.(D) Phenyl.(E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).(F) Biphenyl.(G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).(H) Benzyl.(I) Carboxylic acid.(J) Ester.(K) Ether.(L) Phenylpropylamido.(M) Phenylpropylamino.</p> <p>c. Whether or not the substituent at the 3 position of the pyrazole ring, disregarding the linkage, is further substituted to any extent.</p> <p>d. Whether or not further substituted on the pyrazole ring to any extent.</p>	<p>3/4/2015 – introduced in House and referred to Committee on Criminal Justice and Public Safety.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 5 of 9)</p>	<p>(8) Any compound containing a naphthalene ring system with a substituent on the 1 position carbon atom and bearing an additional substituent at the 4 position of the naphthalene ring system, with a linkage connecting the ring system to the substituent:</p> <p style="padding-left: 40px;">a. Where the linkage connecting the naphthalene ring system to the substituent at its 4 position is any of the following: (A) Alkyl.(B) Carbonyl.(C) Ester.(D) Thione.(E) Thioester.(F) Amino.(G) Alkylamino.(H) Amido.(I) Alkylamido.</p> <p style="padding-left: 40px;">b. Where the substituent at the 4 position of the naphthalene ring system is, disregarding the linkage, any of the following groups: (A) Naphthyl.(B) Quinoliny.(C) Adamantyl.(D) Phenyl.(E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).(F) Biphenyl.(G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).(H) Benzyl.(I) Carboxylic acid.(J) Ester.(K) Ether.(L) Phenylpropylamido. (M) Phenylpropylamino.</p> <p style="padding-left: 40px;">c. Whether or not the substituent at the 4 position of the naphthalene ring system, disregarding the linkage, is further substituted to any extent.</p> <p style="padding-left: 40px;">d. Whether or not further substituted on the naphthalene ring system to any extent.</p> <p>(9) Any compound containing a carbazole ring system with a substituent on the nitrogen atom and bearing an additional substituent at the 1, 2, or 3 position of the carbazole ring system, with a linkage connecting the ring system to the substituent:</p> <p style="padding-left: 40px;">a. Where the linkage connecting the carbazole ring system to the substituent at its 1, 2, or 3 position is any of the following: (A) Alkyl.(B) Carbonyl.(C) Ester.(D) Thione.(E) Thioester.(F) Amino.(G) Alkylamino.(H) Amido.(I) Alkylamido.</p>	<p>3/4/2015 – introduced in House and referred to Committee on Criminal Justice and Public Safety.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 6 of 9)</p>	<p>b. Where the substituent at the 1, 2, or 3 position of the carbazole ring system is, disregarding the linkage, any of the following groups: (A) Naphthyl.(B) Quinolinylnyl.(C) Adamantyl.(D) Phenyl.(E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).(F) Biphenyl.(G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).(H) Benzyl.(I) Carboxylic acid.(J) Ester.(K) Ether.(L) Phenylpropylamido. (M) Phenylpropylamino.</p> <p>c. Whether or not the substituent at the 1, 2, or 3 position of the carbazole ring system, disregarding the linkage, is further substituted to any extent.</p> <p>d. Whether or not further substituted on the carbazole ring system to any extent.</p> <p>(10) Any substance which includes, but is not limited to the following: (1) QUCHIC/BB-22; (2) STS-135; (3) APICA/SDB-001; (4) ADBICA; (5) ADB-FUBINACA; (6) AB-001; (7) SDB-006; (8) EG-018; (9) CB-13; (10) 5-chloro-UR-144; (11) FUB-PB-22.</p> <p>(11) Any synthetic cathinone, which shall be defined as any of the following chemical structures, their salts, isomers and salts of isomers, whenever the existence of these is possible within the specific chemical designation, including any compound structurally derived from 2-aminopropanal by substitution at the 1-position with a monocyclic or fused polycyclic ring system, including compounds further modified by:</p> <p>a. Substitution on the ring system to any extent (including, but not limited to alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents), whether or not further substituted in the ring system by other substituents; and/or</p>	<p>3/4/2015 – introduced in House and referred to Committee on Criminal Justice and Public Safety.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 7 of 9)</p>	<p>b. Substitution at the 3-position with a saturated or unsaturated hydrocarbon substituent; and/or</p> <p>c. Mono- or di- substitution at the 2-amino nitrogen atom with saturated or unsaturated hydrocarbon groups, or inclusion of the 2-amino nitrogen atom in a cyclic structure, whether or not that cyclic structure contains any further substitutions;</p> <p>d. Includes, but is not limited to: 3,4-dimethylmethcathinone (3,4-DMMC); Beta-keto-ethylbenzodioxolylbutanamine (eutylone); 3,4-methylenedioxy-N-ethylcathinone (ethylone).</p> <p>e. 4-methoxymethcathinone (methedrone) This term shall not include substances that are otherwise scheduled under the Controlled Substances Act: (e.g. cathinone, methcathinone, methylone, mephedrone, MDPV, diethylpropion, pyrovalerone), are FDA-approved pharmaceutical products (i.e. bupropion) or are FDA-approved research products.</p> <p>(12) (l) Any synthetic psychoactive compound or substance which shall be defined as substances and their salts, isomers, and salts of isomers, wherever the existence of these is possible, within the following specific chemical designation:</p> <p>a. 2,5-dimethoxy-4-methyl-N-(2-methoxybenzyl) phenethylamine (also known as 25D-NBOMe);</p> <p>b. 2,5-dimethoxy-4-ethyl-N-(2-methoxybenzyl) phenethylamine (also known as 25E-NBOMe);</p> <p>c. 2,5-dimethoxy-4-nitro-N-(2-methoxybenzyl) phenethylamine (also known as 25N-NBOMe);</p> <p>d. 2,5-dimethoxy-4-n-propyl-N-(2-methoxybenzyl) phenethylamine (also known as 25P-NBOMe);</p> <p>e. 2,5-dimethoxy-4-ethylthio-N-(2-methoxybenzyl) phenethylamine (also known as 25T2-NBOMe);</p>	<p>3/4/2015 – introduced in House and referred to Committee on Criminal Justice and Public Safety.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 8 of 9)</p>	<ul style="list-style-type: none"> f. 2,5-dimethoxy-4-sec-propylthio-N-(2-methoxybenzyl)phenethylamine (also known as 25T4-NBOMe); g. 2,5-dimethoxy-4-n-propylthio-N-(2-methoxybenzyl)phenethylamine (also known as 25T7-NBOMe); h. N-(2-methoxybenzyl)-3,4-dimethoxyamphetamine (also known as 34-DMA NBOMe); i. 1-(1-Benzofuran-2-yl)propan-2-amine (also known as 2-APB); j. 5-(2-aminopropyl)-2,3-dihydrobenzofuran (also known as 5-APDB); k. 2-(2-ethylaminopropyl)benzofuran (also known as 2-EAPB); l. 1-(Benzofuran-5-yl)-N-methylpropan-2-amine (also known as 5-MAPB); m. 3,4-dichloromethylphenidate; n. 5,6-methylenedioxy-2-aminoindan (also known as 5,6-MDAI); o. 4-hydroxy-diethyltryptamine (also known as 4-hydroxy-DET); p. 4-methoxyphencyclidine (also known as 4-methoxy-PCP or methoxydine); q. 3,4-dichloro-N-([1-(dimethylamino)cyclohexyl]methyl)benzamide (also known as AH-7921); r. Benocyclidine (also known as BTCP); s. Methoxetamine (also known as MXE); t. 3-Methyl-6-[3-trifluoromethyl]phenyl]-1,2,4-triazolo[4,3-b]pyridazine (also known as CL218872); u. 1-(1,2-diphenylethyl)piperidine (also known as diphenidine); v. 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (also known as MT-45); w. (3-diethylamino-2,2-dimethylpropyl)-4-nitrobenzoate (also known as nitrocaine or nitracaine); x. (E)-4-chloro-N-1(phenylethylpiperidin-2-ylidene)sulfonamide (also known as W-15); 	<p>3/4/2015 – introduced in House and referred to Committee on Criminal Justice and Public Safety.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
New Hampshire 2015 SB 106 (Continued) (Page 9 of 9)	<ul style="list-style-type: none"> y. (E)-4-chloro-N-(1-(4-nitrophenylethyl)piperidin-2-ylidene)sulfonamide (also known as W-18); z. 4-fluoroamphetamine; aa. 1-(thiophen-2-yl)-2-methylaminopropane (also known as methiopropamine). <p>(13) This definition shall not include:</p> <ul style="list-style-type: none"> a. Endocannabinoids that are naturally found in the human body b. Delta-9 Tetrahydrocannabinol (THC) or other marijuana-derived cannabinoids, in the form of marinol, dronabinol, or another generic pharmaceutical equivalent, provided the medication has been issued as the result of a valid prescription; or c. (3) Any other drugs that have cannabinoid receptor activity that are currently approved by the United States Food and Drug Administration for medical use; or marijuana and extracts of marijuana authorized for therapeutic use pursuant to RSA 126-X. 	3/4/2015 – introduced in House and referred to Committee on Criminal Justice and Public Safety.
New Jersey	No pending proposed regulations.	
New Mexico 2015 HB 160	Provides that term “controlled substance” does not include “industrial hemp or marijuana for purpose of or conduct pursuant to and in compliance with the Cannabis Revenue and Freedom Act.”	1/22/2015 – referred to committees.
New Mexico 2015 HB 294	Moves the following combination products to Schedule II: <ul style="list-style-type: none"> (1) not more than three hundred milligrams of dihydrocodeinone, or any of its salts, per one hundred milliliters or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; or (2) not more than three hundred milligrams of dihydrocodeinone, or any of its salts, per one hundred milliliters or not more than fifteen milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts. 	2/18/2015 – “do pass” committee report adopted.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
New Mexico 2015 SB 94	Among other provisions, provides that “the enumeration of marijuana, tetrahydrocannabinols or chemical derivatives of tetrahydrocannabinol as Schedule I controlled substances does not apply to: (1) research and development of industrial hemp by qualified entities pursuant to rules adopted by the New Mexico department of agriculture.”	3/6/2015 – passed House.
New York 2015 AB 627	Adds the following substances to Schedule I: <ul style="list-style-type: none"> (1) N-(2-methoxybenzyl)-2, 5-dimethoxy-4-iodophenethylamine, also known as 25I-NBOME, 2C-1-NBOME; Cimbi-5, its optical isomers, salts and salts of isomers; (2) 2,5-dimethoxy-4-iodophenethylamine (2C-1), its optical isomers, salts and salts of isomers; (3) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, also known as, 25 CNBOME; 2C-C-NBOME; 25C; Cimbi-82, its optical, positional, and geometric isomers, salts and salts of isomers; (4) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, also known as, 25 BNBOME; 2C-B-NBOME; Cimbi-36, its optical, positional, and geometric isomers, salts and salts of isomers. 	1/7/2015 – referred to Committee on Assembly Health.
New York 2015 AB 1910 (Page 1 of 4)	Adds the following substances to Schedule I: <ul style="list-style-type: none"> (1) Synthetic cannabinoids. Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric), homologues (analogues), and salts of isomers and homologues (analogues), unless specifically exempted, within the specific chemical designation: 	1/13/2015 – introduced and referred to Committee on Assembly Health.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
New York 2015 AB 1910 (Continued) (Page 2 of 4)	Adds the following substances to Schedule I: (2) Naphthoylindoles. Any compound containing a 3-(1-Naphthyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. (Other names in this structural class include but are not limited to: JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398, AM-2201, and WIN 55212); (3) Naphthylmethylindoles. Any compound containing a 1 H-indol-3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. (Other names in this structural class include but are not limited to: JWH-175 and JWH-184); (4) Naphthoylpyrroles. Any compound containing a 3-(1-naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. (Other names in this structural class include but are not limited to: JWH-307);	1/13/2015 – introduced and referred to Committee on Assembly Health.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>New York</p> <p>2015 AB 1910 (Continued) (Page 3 of 4)</p>	<p>Adds the following substances to Schedule I:</p> <p>(5) Naphthylmethylindenes. Any compound containing a naphthylmethyl indene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. (Other names in this structural class include but are not limited to: JWH-176);</p> <p>(6) Phenylacetylindoles. Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. (Other names in this structural class include but are not limited to: RCS-8 (SR-18), JWH-250, JWH-203, JWH-251, and JWH-302);</p> <p>(7) Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not substituted in the cyclohexyl ring to any extent. (Other names in this structural class include but are not limited to: CP 47,497 (and homologues (analogs)), cannabicyclohexanol, and CP 55,940);</p>	<p>1/13/2015 – introduced and referred to Committee on Assembly Health.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
New York 2015 AB 1910 (Continued) (Page 4 of 4)	Adds the following substances to Schedule I: (8) Benzoylindoles. Any compound containing a 3-(benzoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. (Other names in this structural class include but are not limited to: AIVI 694, Pravadoline (WIN 48,098), RCS 4, and AM-679); (9) Adamantoylindoles. Any compound containing a 3-(1-adamantoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the adamantyl ring system to any extent. (Other names in this structural class include but are not limited to: AM-1248); (10) 2,3-Dihydro-5-methyl-3(4-morpholinylmethyl)pyrrolo 1,2,3-de-1, 4-benzoaxin-6-yl-1-1-naphthalenylmethanone. (Other names in this structural class include but are not limited to: WIN 55,212-2); (11) (6aR, 10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl) -6a,7,10,10a-tetrahydrobenzocchromen-1-ol. (Other names in this structural class include but are not limited to: HU-210); (12) (6aS,10aS)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl) -6a,7,10,10-a-tetrahydrobenzo c chromen-1-ol (Dexanabinol or HU-211); (13) Aminoalkylindoles. Including but not limited to 2,2,3,3-tetramethylcyclopropyl indoles (other names include (1-(5-fluoropentyl)-1H-indol-3-yl) (2,3,3-tetramethylcyclopropyl) methanone or XLR-11 and (1-pentyl-1H-indol -3-yl) (2,2,3,3-tetramethylcyclopropyl)methanone or UR-144).	1/13/2015 – introduced and referred to Committee on Assembly Health.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
New York 2015 AB 3089	Among many other provisions, removes marijuana from Schedule I.	3/2/2015 – amend and recommit to Committee on Assembly Codes.
New York 2015 AB 4059	Adds provision to New York law that the state controlled substance schedules include any substances “designated pursuant to the federal Analog Act (21 U.S.C. § 813).”	1/29/2015 – introduced and referred to Committee on Assembly Health.
New York 2015 AB 4579	Adds the following substances to Schedule I: (1) "Synthetic cannabinoid" means any material, compound, mixture or preparation containing any quantity of: <ol style="list-style-type: none"> a. CP 47,497 and homologues: 2-5-(2-methyloctan-2-yl)phenol; b. HU-210; c. HU-211: (dexanabinol, (6aS, 10aS)-9-(hydroxymethyl) -6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo chromen-1-ol); d. JWH-o18: 1-Pentyl-3-(1-naphthoyl)indole; or e. (e) JWH-o73: 1-Butyl-3-(1-naphthoyl)indole. (2) CP 47,497 and homologues: 2-5-(2-methyloctan-2-yl)phenol; (3) HU-210; (4) HU-211: (dexanabinol, (6aS, 10aS)-9-(hydroxymethyl) -6,6-dimethyl -3-(2-methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo chromen-1-ol); (5) JWH-o18: 1-Pentyl-3-(1-naphthoyl)indole; (6) JWH-o73: 1-Butyl-3-(1-naphthoyl)indole.	2/3/2015 – introduced and referred to Committee on Assembly Health.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
New York 2015 SB 738	Companion bill to 2015 AB 627.	1/7/2015 – introduced and referred to Committee on Senate Health.
New York 2015 SB 1640	Companion bill to 2015 AB 4059	1/13/2015 – introduced and referred to Committee on Senate Health.
New York 2015 SB 1747	Companion bill to 2015 AB 3089	1/14/2015 – introduced and referred to Committee on Senate Health.
New York 2015 SB 2836 (Page 1 of 3)	<p>Adds the following substances to Schedule I:</p> <p>(1) “Synthetic cannabinoid” means any material, compound, mixture or preparation containing any quantity of:</p> <ul style="list-style-type: none"> a. Tetrahydrocannabinols, naphthoylindoles, naphthylmethylindoles, naphthoylpyrroles, naphthylideneindenes, phenylacetylindoles, cyclohexylphenols, benzoylindoles, or adamantoylindoles, as defined in section thirty-three hundred six of this title; b. (6aR, 10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzocchromen-1-ol (HU-210); c. (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzocchromen-1-ol (Dexanabinol or HU-211); or d. 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo1,2,3-de-1, 4-benzoxazin-6-y1-1-naphthalenylmethanone (WIN 55,212-2). 	1/29/2015 – introduced and referred to Committee on Senate Health.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>New York</p> <p>2015 SB 2836 (Continued) (Page 2 of 3)</p>	<p>Adds the following substances to Schedule I:</p> <ul style="list-style-type: none"> (2) Naphthoylindoles. Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent; (3) Naphthylmethylindoles. Any compound containing a H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent; (4) Naphthoylpyrroles. Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent; (5) Naphthylideneindenes. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent; (6) Phenylacetylindoles. Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. 	<p>1/29/2015 – introduced and referred to Committee on Senate Health.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
New York 2015 SB 2836 (Continued) (Page 3 of 3)	Adds the following substances to Schedule I: (7) Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent; (8) Benzoylindoles. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent; (9) Adamantoylindoles. Any compound containing a 3-(1-adamantoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperindinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the adamantyl ring system to any extent; (10) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) -6a,7,10,10a-tetrahydrobenzocchromen-1-ol (HU-210); (11) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) -6a,7,10,10a-tetrahydrobenzocchromen-1-ol (Dexanabinol or HU-211); (12) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo1,2,3-de-1, 4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2).	1/29/2015 – introduced and referred to Committee on Senate Health.
North Carolina	No pending proposed legislation.	

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
<p>North Dakota</p> <p>2015 SB 2100 (Page 1 of 5)</p>	<p>Adds the following to Schedule I: Acetylfentanyl (also known as N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);</p> <p>Indole carboxaldehydes. Any compound structurally derived from 1H-indole-3-carboxaldehyde or 1H-2-carboxaldehyde substituted in both of the following ways: at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group; and, at the hydrogen of the carboxaldehyde by a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group whether or not the compound is further modified to any extent in the following ways:</p> <ol style="list-style-type: none"> (1) Substitution to the indole ring to any extent; or (2) Substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group to any extent; or (3) A nitrogen heterocyclic analog of the indole ring; or (4) A nitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring. (5) Examples include: <ol style="list-style-type: none"> a. 1-Pentyl-3-(1-naphthoyl)indole - Other names: JWH-018 and AM-678; b. 1-Butyl-3-(1-naphthoyl)indole - Other names: JWH-073; c. 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole - Other names: JWH-081; d. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole - Other names: JWH-200; e. 1-Propyl-2-methyl-3-(1-naphthoyl)indole - Other names: JWH-015; f. 1-Hexyl-3-(1-naphthoyl)indole - Other names: JWH-019; g. 1-Pentyl-3-(4-methyl-1-naphthoyl)indole - Other names: JWH-122; 	<p>3/20/2015 – signed by Governor.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>North Dakota</p> <p>2015 SB 2100 (Continued) (Page 2 of 5)</p>	<p>Adds the following to Schedule I:</p> <p>h. 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole - Other names: JWH-210;</p> <p>i. 1-Pentyl-3-(4-chloro-1-naphthoyl)indole - Other names: JWH-398;</p> <p>j. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole - Other names: AM-2201;</p> <p>k. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole - Other names: RCS-8;</p> <p>l. 1-Pentyl-3-(2-methoxyphenylacetyl)indole - Other names: JWH-250;</p> <p>m. 1-Pentyl-3-(2-methylphenylacetyl)indole - Other names: JWH-251;</p> <p>n. 1-Pentyl-3-(2-chlorophenylacetyl)indole - Other names: JWH-203;</p> <p>o. 1-Pentyl-3-(4-methoxybenzoyl)indole - Other names: RCS-4;</p> <p>p. (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole) - Other names: AM-694;</p> <p>q. (4-Methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone - Other names: WIN 48,098 and Pravadoline;</p> <p>r. (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl) methanone -- Other names: UR-144;</p> <p>s. (1-(5-fluoropentyl)indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone - Other names: XLR-11;</p> <p>t. (1-(2-morpholin-4-ylethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone - Other names: A-796,260;</p> <p>u. (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone -- Other names: THJ-2201;</p> <p>v. 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone -- Other names: THJ-018;</p>	<p>3/20/2015 – signed by Governor.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>North Dakota</p> <p>2015 SB 2100 (Continued) (Page 3 of 5)</p>	<p>Adds the following to Schedule I:</p> <ul style="list-style-type: none"> w. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone - Other names: FUBIMINA; x. 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl) indole - Other names: AM-1248; y. 1-Pentyl-3-(1-adamantoyl)indole - Other names: AB-001 and JWH-018 adamantyl analog. <p>Indole carboxamides. Any compound structurally derived from 1H-indole-3-carboxamide or 1H-2-carboxamide substituted in both of the following ways: at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidiny)methyl, 1-(N-methyl-3-morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group; and, at the nitrogen of the carboxamide by a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group whether or not the compound is further modified to any extent in the following ways:</p> <ul style="list-style-type: none"> (1) Substitution to the indole ring to any extent; or (2) Substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group to any extent; or (3) A nitrogen heterocyclic analog of the indole ring; or (4) A nitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring. (5) Examples include: <ul style="list-style-type: none"> a. N-Adamantyl-1-pentyl-1H-indole-3-carboxamide - Other names: JWH-018 adamantyl carboxamide, APICA, SDB-001, and 2NE1; b. N-Adamantyl-1-fluoropentylindole-3-carboxamide - Other names: STS-135; c. N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide - Other names: AKB 48 and APINACA; d. N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide - Other names: NNEI and MN-24. 	<p>3/20/2015 – signed by Governor.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>North Dakota</p> <p>2015 SB 2100 (Continued) (Page 4 of 5)</p>	<p>Adds the following to Schedule I:</p> <ul style="list-style-type: none"> e. N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide - Other names: ADBICA; f. (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide - Other names: AB-PINACA; g. N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide - Other names: AB-FUBINACA; h. (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide - Other names: 5-Fluoro AB-PINACA; i. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide - Other names: ADB-PINACA; j. N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide - Other names: AB-CHMINACA; k. N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide - Other names: ADB-FUBINACA; l. N-((3s,5s,7s)-adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide - Other names: FUB-AKB48 and AKB48 N-(4-fluorobenzyl) analog; m. 1-(5-fluoropentyl)-N-(quinolin-8-yl)-1H-indazole-3-carboxamide - Other names: 5-fluoro-THJ; n. (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate - Other names: 5-fluoro AMB; o. methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate - Other names: FUB-AMB. 	<p>3/20/2015 – signed by Governor.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>North Dakota</p> <p>2015 SB 2100 (Continued) (Page 5 of 5)</p>	<p>Indole carboxylic acids. Any compound structurally derived from 1H-indole-3-carboxylic acid or 1H-2-carboxylic acid substituted in both of the following ways: at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, tetrahydropyranymethyl, benzyl, or halo benzyl group; and, at the hydroxyl group of the carboxylic acid by a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group whether or not the compound is further modified to any extent in the following ways:</p> <ol style="list-style-type: none"> (1) Substitution to the indole ring to any extent; or (2) Substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, propionaldehyde group to any extent; or (3) A nitrogen heterocyclic analog of the indole ring; or (4) A nitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring. (5) Examples include: <ol style="list-style-type: none"> a. 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester - Other names: BB-22 and QUCHIC; b. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate - Other names: FDU-PB-22; c. 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester - Other names: PB-22 and QUPIC; d. 1-(5-Fluoropentyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester - Other names: 5-Fluoro PB-22 and 5F-PB-22; e. quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate - Other names: FUB-PB-22; f. [6] naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate - Other names: NM2201. 	<p>3/20/2015 – signed by Governor.</p>
<p>Ohio</p>	<p>No pending proposed legislation.</p>	

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Oklahoma</p> <p>2015 HB 1616 (Page 1 of 3)</p>	<p>Adds the following substances to Schedule I:</p> <ol style="list-style-type: none"> (1) Methoxetamine; (2) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADBICA); (3) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA); (4) N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide (NNE1); (5) 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide (5F-NNE1); (6) N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006); (7) N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-SDB-006). <p>Indole Esters: Any compound containing a 1H-Indole-3-carboxylate structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxylate group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole Esters include, but are not limited to:</p> <ol style="list-style-type: none"> (1) quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22); (2) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22); (3) quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate (BB-22); (4) naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22); (5) naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201) 	<p>3/18/2015 – second reading in Senate; referred to Health and Human Services Committee.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Oklahoma</p> <p>2015 HB 1616 (Continued) (Page 2 of 3)</p>	<p>Adds the following substances to Schedule I:</p> <p>Adamantanoylindoles: Any compound containing an adamantanyl-(1H-indol-3-yl)methanone structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Adamantanoylindoles include, but are not limited to:</p> <ul style="list-style-type: none"> (1) adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]methanone (AM1248), or (2) adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-001); <p>Carbazole Ketone: Any compound containing (9H-carbazole-3-yl)methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole Ketones include, but are not limited to, naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone (EG-018).</p>	<p>3/18/2015 – second reading in Senate; referred to Health and Human Services Committee.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Oklahoma</p> <p>2015 HB 1616 (Continued) (Page 3 of 3)</p>	<p>Adds the following substances to Schedule I:</p> <p>Benzimidazole Ketone: Any compound containing (benzimidazole-2-yl) methanone structure with or without substitution at either nitrogen atom of the benzimidazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinoliny, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinoliny, or cycloalkyl rings to any extent.</p> <p>Benzimidazole Ketones include, but are not limited to:</p> <ol style="list-style-type: none"> (1) naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-yl)methanone (JWH-018 benzimidazole analog), or (2) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone (FUBIMINA). <p>Removes “Hydrocodone with another active ingredient” from Schedule III.</p>	<p>3/18/2015 – second reading in Senate; referred to Health and Human Services Committee.</p>
<p>Oregon</p>	<p>No pending proposed regulations.</p>	
<p>Pennsylvania</p>	<p>No pending proposed legislation.</p>	
<p>Rhode Island</p> <p>2015 SB 509</p>	<p>Adds the following substances to Schedule I:</p> <p>“Any synthetic cannabinoid or cathinone not regulated by the federal Food and Drug Administration, or by state law that binds to the cannabinoid receptor(s) and/or mimics the pharmacological response of a schedule I or II controlled substance as determined by the process described in § 21-28-7.0 shall be considered a schedule I substance.”</p>	<p>3/3/2015 – committee recommends measure be held for further study.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
South Carolina	No pending proposed legislation.	
<p>South Dakota</p> <p>2015 SB 61 (Page 1 of 3)</p>	<p>Revises the description of synthetic cannabinoids in Schedule I as follows (text added <u>in underline</u>):</p> <p>Synthetic cannabinoids. Any material, compound, mixture, or preparation that is not listed as a controlled substance in another schedule, is not an FDA-approved drug, and contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric), homologues, <u>modifications of the indole ring by nitrogen heterocyclic analog substitution or nitrogen heterocyclic analog substitution of the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, cumyl, or propionaldehyde structure</u>, and salts of isomers, homologues, <u>and modifications</u>, unless specifically excepted, whenever the existence of these salts, isomers, homologues, modifications, and salts of isomers, homologues, <u>and modifications</u> is possible within the specific chemical designation:</p> <p>Makes slight changes to the following descriptions in Schedule I: Naphthoylindoles, Naphthylmethylindoles, Phenylacetylindoles, Benzoylindoles, Naphthoylpyrroles, Naphthylmethylindenes, Cyclohexylphenols, Substituted Acetylindoles, Substituted Carboxamide Indole</p> <p>Adds the following paragraph to Schedule I:</p> <p>Substituted Carboxylic Acid Indole. Any compound containing a 1H-indole-2-carboxylic acid or 1H-indole-3-carboxylic acid substituted at the hydroxyl group of the carboxylic acid with a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, quinolinyl, isquinolinyl, cumyl, or propionaldehyde substituent whether or not further substituted on the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, cumyl, quinolinyl, isquinolinyl, or propionaldehyde substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group whether or not further substituted on the indole ring to any extent.</p>	<p>2/18/2015 – Signed by Governor; effective 2/18/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>South Dakota</p> <p>2015 SB 61 (Continued) (Page 2 of 3)</p>	<p>Adds the following substances to Schedule II:</p> <ul style="list-style-type: none"> (1) Morphine, except when it meets subdivision 34-20B-23(8); (2) Hydrocodone (Dihydrocodeinone); (3) Codeine, except when it meets subdivision 34-20B-23(1), 34-20B-23(2), or 34-20B-26(1); (4) Dihydrocodeine, except when it meets subdivision 34-20B-23(5) or 34-20B-26(2); (5) Ethylmorphine, except when it meets subdivision 34-20B-23(6) or 34-20B-26(3); (6) Oxycodone; and (7) Hydromorphone. <p>Removes the following two combination products from Schedule III:</p> <ul style="list-style-type: none"> (1) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of isoquinoline alkaloid of opium; and (2) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts. <p>Adds the following substances to Schedule IV:</p> <ul style="list-style-type: none"> (1) Alprazolam; (2) Midazolam; (3) Temazepam; (4) Alfaxalone, 5[alpha]-pregnan-3[alpha]-ol-11,20-dione, including its salts, isomers, and salts of isomers; (5) Tramadol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers; and (6) Suvorexant, including its salts, isomers, and salts of isomers. 	<p>2/18/2015 – Signed by Governor; effective 2/18/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>South Dakota</p> <p>2015 SB 61 (Continued) (Page 3 of 3)</p>	<p>Amends Schedule IV to change the phrase “not more than 0.5 milligrams of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit” to “not more than 1 milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit.”</p>	<p>2/18/2015 – Signed by Governor; effective 2/18/2015.</p>
<p>Tennessee</p> <p>2015 HB 287 (Page 1 of 7)</p>	<p>Adds the following hallucinogenic substances to Schedule I:</p> <ol style="list-style-type: none"> (1) 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36; (2) 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82; (3) 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5; (4) 3,4-Methylenedioxy-N-methylcathinone; Other names: Methylone; (5) 4-Methylmethcathinone; Other names: Mephedrone; Methpadrone; 4-MMC; (6) 3,4-Methylenedioxypyrovalerone; Other names: MDPV; (7) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); (8) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D); (9) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); (10) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); (11) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2); (12) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4); (13) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); (14) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); (15) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); (16) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: UR-144; 1-pentyl-3-(2,2,3,3-tetramethylcyclopropyl)indole; 	<p>3/18/2015 - placed on calendar for Finance, Ways & Means Subcommittee for 3/25/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Tennessee</p> <p>2015 HB 287 (Continued) (Page 2 of 7)</p>	<p>Adds the following hallucinogenic substances to Schedule I:</p> <p>(17) [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: 5-fluoro-UR-144; 5-F-UR-144; XLR-11; 1-(5-fluoro-pentyl)-3-(2,2,3,3-tetramethylcyclopropyl)indole;</p> <p>(18) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: APINACA; AKB-48.</p> <p>Adds "ET" and "Trip" as other names for Alpha-ethyltryptamine; specifies that "Constituent of 'Peyote' cacti" is another name for Mescaline; specifies that Psilocybin and Psilocyn are constituents of magic mushrooms; and removes the following from the schedule: 55H-NBOMe, being any compound structurally derived from 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine structure with substitution in either phenyl ring to any extent; including, but not limited to 25I-NBOMe, 25-B-NBOMe, or 25C-NBOMe. This bill also revises from "TCP" to "TCPy" the other name for 1-[1-(2-Thienyl)cyclohexyl]piperidine.</p> <p>Adds the following stimulants to Schedule I:</p> <p>(1) Alpha-pyrrolidinobutiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: [alpha]-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one;</p> <p>(2) Alpha-pyrrolidinopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: [alpha]-PVP; [alpha]-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one;</p> <p>(3) Butylone, its optical, positional, and geometric isomers, salts, and salts of isomers;</p> <p>(4) Alpha-pyrrolidinobutiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: [alpha]-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one;</p>	<p>3/18/2015 - placed on calendar for Finance, Ways & Means Subcommittee for 3/25/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Tennessee 2015 HB 287 (Continued) (Page 3 of 7)	Adds the following stimulants to Schedule I: (5) Alpha-pyrrolidinopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: [alpha]-PVP; [alpha]-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one; (6) Butylone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one; (7) 3-Fluoro-N-methylcathinone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: 3-FMC; 1-(3-fluorophenyl)-2-(methylamino)propan-1-one; (8) 4-Fluoro-N-methylcathinone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: 4-FMC; flephedrone; 1-(4-fluorophenyl)-2-(methylamino)propan-1-one; (9) 4-Methyl-N-ethylcathinone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)propan-1-one; (10) 4-Methyl-alpha-pyrrolidinopropiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: 4-MePPP; MePPP; 4-methyl-[alpha]-pyrrolidinopropiophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one; (11) Naphyrone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one; (12) Pentedrone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: [alpha]-methylaminovalerophenone; 2-(methylamino)-1-phenylpentan-1-one; (13) Pentylone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one.	3/18/2015 - placed on calendar for Finance, Ways & Means Subcommittee for 3/25/2015.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Tennessee 2015 HB 287 (Continued) (Page 4 of 7)	Adds "constituent of Catha edulis or 'Khat' plant" under "other names" for Cathinone. Adds the following "Cannabimimetic agents" to Schedule I: (1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497); (2) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog); (3) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678); (4) 1-Butyl-3-(1-naphthoyl)indole (JWH-073); (5) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019); (6) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); (7) 1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250); (8) 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081); (9) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); (10) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398); (11) 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201); (12) 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694); (13) 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and RCS-4); (14) 1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole 7008 (SR-18 and RCS-8); (15) 1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203); (16) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers; Other name: AB-FUBINACA; (17) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers; Other name: ADB-PINACA; (18) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: 5-fluoro-PB-22; 5F-PB-22;	3/18/2015 - placed on calendar for Finance, Ways & Means Subcommittee for 3/25/2015.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Tennessee</p> <p>2015 HB 287 (Continued) (Page 5 of 7)</p>	<p>Adds the following “Cannabimimetic agents” to Schedule I: (19) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: PB-22; QUPIC.</p> <p>In regard to Schedule III, adds Perampanel, and its salts, isomers, and salts of isomers. This bill also makes a change to the chemical name under "other names" for Ketamine.</p> <p>In regard to Schedule III, Narcotic drugs, present law includes any material, compound, mixture, or preparation containing the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities:</p> <ol style="list-style-type: none"> (1) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; (2) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts; and (3) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts. <p>This bill deletes the above provisions and instead includes: not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.</p>	<p>3/18/2015 - placed on calendar for Finance, Ways & Means Subcommittee for 3/25/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Tennessee</p> <p>2015 HB 287 (Continued) (Page 6 of 7)</p>	<p>In regard to Schedule III, Anabolic steroids, this bill adds the following to the schedule:</p> <ol style="list-style-type: none"> (1) Chlorotestosterone (which, under present law, is listed as a "other name" for Clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one); (2) Methandranone; (3) Methasterone (2[alpha],17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one); (4) Prostanazol (17[beta]-hydroxy-5[alpha]-androstano[3,2-c]pyrazole); and (5) Stanolone. <p>Adds the following substances to Schedule IV:</p> <ol style="list-style-type: none"> (1) Alfaxalone; (2) Suvorexant; (3) Dexfenfluramine; (4) Lorcaserin. <p>Adds Ezogabine to Schedule V.</p> <p>Removes the following compounds that are structurally derived from 2-amino-1-phenyl-1-propanone by modification:</p> <ol style="list-style-type: none"> (1) 3,4-methylenedioxymethcathinone (Methylone); (2) 3,4-methylenedioxypropylvalerone (MDPV); (3) 4-methylmethcathinone (Mephedrone, Methpadrone, 4-MMC); (4) 4-fluoromethcathinone (Flephedrone); (5) 3-fluoromethcathinone (3-FMC); (6) 2-(methylamino)-1-phenylpropan-1-one (Ephedrone); (7) alpha-Pyrrolidinopentiophenone (alpha-PVP); (8) Naphthylpyrovalerone (Naphyrone); (9) beta-Keto-N-methylbenzodioxolylpropylamine (Butylone); and (10) beta-Keto-N-methylbenzodioxolylpentanamine (Pentylone). 	<p>3/18/2015 - placed on calendar for Finance, Ways & Means Subcommittee for 3/25/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Tennessee 2015 HB 287 (Continued) (Page 7 of 7)	The state Senate adopted an amendment passed Senate Bill 318, as amended, adding 25H-NBOMe, being any compound structurally derived from 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine structure with substitution in either phenyl ring to any extent, to the list of Schedule I, Hallucinogenic substances; removes F-PB-22 from the list of prohibited synthetic cannabinoids; and clarifies that derivatives of hydroxymitragynine are controlled substances.	3/18/2015 - placed on calendar for Finance, Ways & Means Subcommittee for 3/25/2015.
Tennessee 2015 SB 318	Companion bill to 2015 HB 287.	3/19/2015 – received by House after passage in Senate.
Tennessee 2015 SB 932	Adds the following substances to Schedule I: <ul style="list-style-type: none"> (1) Naphthoylindazoles, being any compound structurally derived from 3-(1-naphthoyl) indazole structure with substitution at the nitrogen atom of the indazole ring, whether or not further substituted in the indazole ring to any extent, whether or not substituted in the naphthyl ring to any extent; including, but not limited to THJ-2201; (2) Methylindazolecarboxamidobutanoate, being any compound structurally derived from methyl-2-(indazole-3-carboxamido) butanoate structure with substitution at the nitrogen atom of the indazole ring whether or not further substituted in the indazole ring to any extent, whether or not substituted in the butanyl or methyl chain around the ester to any extent; including, but not limited to AMB and fluoro-AMB; <p>Change the term “Quinolinyndolecarboxesters” in Schedule I to “Quinolinyndolecarboxylate.”</p>	2/19/2015 – passed on second consideration; referred to Judiciary Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Texas 2015 HB 488	<p>Adds the following substances to Penalty Group 2:</p> <ol style="list-style-type: none"> (1) 5-(2-aminopropyl)benzofuran (5-APB); (2) 6-(2-aminopropyl)benzofuran (6-APB); (3) 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB); (4) 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-APDB); (5) 5-(2-aminopropyl)indole (Trade or other names: 5-IT, 5-API); (6) 6-(2-aminopropyl)indole (Trade or other names: 6-IT, 6-API); (7) Benzothiophenylcyclohexylpiperidine (BTCPP); (8) 8-bromo-alpha-methyl-benzo[1,2-b:4,5-b']difuran- 4-ethanamine (Trade or other name: Bromo-DragonFLY); (9) Desoxypipradrol (2-benzhydrylpiperidine); (10) Diphenylprolinol (diphenyl(pyrrolidin-2-yl) methanol, D2PM); (11) 2-ethylamino-2-(3-methoxyphenyl)cyclohexanone (Trade or other name: methoxetamine); (12) 5-iodo-2-aminoindane (5-IAI); (13) 5-methoxy-N, N-diallyltryptamine (5MeO-DALT); (14) 4-methoxymethamphetamine (PMMA); (15) 2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone (Trade or other names: 2-MeO-ketamine; methoxyketamine); (16) 5,6-methylenedioxy-2-aminoindane (MDAI); (17) O-Acetylpsilocin (Trade or other name: 4-Aco-DMT); (18) Etaqualone and its salts; (19) 4-Methoxymethcathinone (Also known as Methedrone); (20) JWH-405; [and] benzoylindoles structurally derived from 3-(1-naphthoyl)indole with or without substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl) methyl, cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent, including: (21) 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4); and (22) 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-methoxybenzoyl)indole (Pravadoline or WIN 48,098). 	2/12/2015 – referred to Criminal Jurisprudence Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
Texas 2015 HB 595 (Page 1 of 3)	Adds the following substances to Penalty Group 1-A: Compounds structurally derived from 2,5-dimethoxyphenethylamine by substitution at the 1-amino nitrogen atom with a benzyl substituent, including: compounds further modified by: substitution in the phenethylamine ring at the 4- position to any extent (including alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents); or substitution in the benzyl ring to any extent (including alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents); and by example, compounds such as: <ol style="list-style-type: none"> (1) 4-Bromo-2,5-dimethoxy-N-(2- methoxybenzyl) phenethylamine (trade or other names: 25B-NBOMe, 2C-B-NBOMe); (2) 4-Chloro-2,5-dimethoxy-N-(2- methoxybenzyl) phenethylamine (trade or other names: 25C-NBOMe, 2C-C-NBOMe); (3) 2,5-Dimethoxy-4-methyl-N-(2- methoxybenzyl) phenethylamine (trade or other names: 25D-NBOMe, 2C-D-NBOMe); (4) 4-Ethyl-2,5-dimethoxy-N-(2- methoxybenzyl)phenethylamine (trade or other names: 25E-NBOMe, 2C-E-NBOMe); (5) 2,5-Dimethoxy-N-(2- methoxybenzyl)phenethylamine (trade or other names: 25H-NBOMe, 2C-H-NBOMe); (6) 4-Iodo-2,5-dimethoxy-N-(2- methoxybenzyl)phenethylamine (trade or other names: 25I-NBOMe, 2C-I-NBOMe); (7) 4-Iodo-2,5-dimethoxy-N- benzylphenethylamine (trade or other name: 25I-NB); (8) 4-Iodo-2,5-dimethoxy-N-(2,3- methylenedioxybenzyl) phenethylamine (trade or other name: 25I-NBMD); (9) 4-Iodo-2,5-dimethoxy-N-(2- fluorobenzyl)phenethylamine (trade or other name: 25I-NBF); (10) 4-Iodo-2,5-dimethoxy-N-(2- hydroxybenzyl)phenethylamine (trade or other name: 25I-NBOH); (11) 2,5-Dimethoxy-4-nitro-N-(2- methoxybenzyl) phenethylamine (trade or other names: 25N-NBOMe, 2C-N-NBOMe); and 	2/19/2015 – referred to Criminal Jurisprudence Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
Texas 2015 HB 595 (Continued) (Page 2 of 3)	<p>Adds the following substances to Penalty Group 1-A:</p> <ul style="list-style-type: none"> (12) 2,5-Dimethoxy-4-(n)-propyl-N-(2- methoxybenzyl) phenethylamine (trade or other names: 25P-NBOMe, 2C-P-NBOMe); <p>Removes the following substances from Penalty Group 2:</p> <ul style="list-style-type: none"> (1) [4-bromo-2, 5-dimethoxyamphetamine (some trade or other names: 4-bromo-2, 5-dimethoxy-alpha-methylphenethylamine; 4-bromo-2, 5-DMA); (2) [4-bromo-2, 5-dimethoxyphenethylamine;] (3) [2, 5-dimethoxy-4-ethylamphetamine (trade or other name: DOET); (4) [2, 5-dimethoxy-4-(n)-propylthiophenethylamine (trade or other name: 2C-T-7);] <p>Adds the following substances to Penalty Group 2:</p> <ul style="list-style-type: none"> (1) alpha-Methylamino-valerophenone (Also known as Pentadrone); (2) 2,5-Dimethoxyphenethylamine and any compound structurally derived from 2,5-Dimethoxyphenethylamine by substitution at the 4-position of the phenyl ring to any extent (including alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents), including, by example, compounds such as: (3) 4-Bromo-2,5-dimethoxyphenethylamine (trade or other name: 2C-B); (4) 4-Chloro-2,5-dimethoxyphenethylamine (trade or other name: 2C-C); (5) 2,5-Dimethoxy-4-methylphenethylamine (trade or other name: 2C-D); (6) 4-Ethyl-2,5-dimethoxyphenethylamine (trade or other name: 2C-E); (7) 4-Iodo-2,5-dimethoxyphenethylamine (trade or other name: 2C-I); (8) 2,5-Dimethoxy-4-nitrophenethylamine (trade or other name: 2C-N); (9) 2,5-Dimethoxy-4-(n)-propylphenethylamine (trade or other name: 2C-P); 	2/19/2015 – referred to Criminal Jurisprudence Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Texas 2015 HB 595 (Continued) (Page 3 of 3)	Adds the following substances to Penalty Group 2: (10) 4-Ethylthio-2,5-dimethoxyphenethylamine (trade or other name: 2C-T-2); (11) 4-Isopropylthio-2,5-dimethoxyphenethylamine (trade or other name: 2C-T-4); (12) 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (trade or other name: 2C-T-7); and (13) 2,5-Dimethoxyamphetamine and any compound structurally derived from 2,5-Dimethoxyamphetamine by substitution at the 4- position of the phenyl ring to any extent (including alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents), including, by example, compounds such as: (14) 4-Ethylthio-2,5-dimethoxyamphetamine (trade or other name: Aleph-2); (15) 4-Isopropylthio-2,5-dimethoxyamphetamine (trade or other name: Aleph-4); (16) 4-Bromo-2,5-dimethoxyamphetamine (trade or other name: DOB); (17) 4-Chloro-2,5-dimethoxyamphetamine (trade or other name: DOC); (18) 2,5-Dimethoxy-4-ethylamphetamine (trade or other name: DOET); (19) 4-Iodo-2,5-dimethoxyamphetamine (trade or other name: DOI); (20) 2,5-Dimethoxy-4-methylamphetamine (trade or other name: DOM); (21) 2,5-Dimethoxy-4-nitroamphetamine (trade or other name: DON); (22) 4-Isopropyl-2,5-dimethoxyamphetamine (trade or other name: DOIP); and (23) 2,5-Dimethoxy-4-(n)-propylamphetamine (trade or other name: DOPR).	2/19/2015 – referred to Criminal Jurisprudence Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
Texas 2015 HB 597 (Page 1 of 4)	<p>Adds the following substances to Penalty Group 2-A</p> <ol style="list-style-type: none"> (1) WIN-55; (2) AM-1220; (3) RCS-8; <p>Benzoylindole: any compound structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent, including:</p> <ol style="list-style-type: none"> (1) AM-630; (2) AM-679; (3) AM-694; (4) AM-1241; (5) Pravadoline (Other name: WIN 48,098); and (6) RCS-4; <p>Adamantoylindole: any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the adamantyl ring to any extent, including:</p> <ol style="list-style-type: none"> (1) AB-001; and (2) AM-1248. 	2/19/2015 – referred to Criminal Jurisprudence Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Texas</p> <p>2015 HB 597 (Continued) (Page 2 of 4)</p>	<p>Adds the following substances to Penalty Group 2-A:</p> <p>Adamantylindolecarboxamide: any compound structurally derived from N-(adamantan-1-yl)-1H-indole-3-carboxamide or N-(adamantan-2-yl)-1H-indole-3-carboxamide by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the adamantyl ring to any extent, including:</p> <ul style="list-style-type: none"> (1) APICA; and (2) STS-135. <p>Adamantylindazolecarboxamide: any compound structurally derived from N-(adamantan-1-yl)-1H-indazole-3-carboxamide or N-(adamantan-2-yl)-1H-indazole-3-carboxamide by substitution at the 1-position nitrogen atom of the indazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indazole ring to any extent, whether or not substituted in the adamantyl ring to any extent, including:</p> <ul style="list-style-type: none"> (1) 5-Fluoro AKB-48; and (2) AKB-48; <p>Aminooxobutylindazolecarboxamide: any compound structurally derived from N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide by substitution at the 1-position nitrogen atom of the indazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indazole ring to any extent, including:</p> <ul style="list-style-type: none"> (1) AB-PINACA; and (2) AB-FUBINACA. 	<p>2/19/2015 – referred to Criminal Jurisprudence Committee.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Texas</p> <p>2015 HB 597 (Continued) (Page 3 of 4)</p>	<p>Adds the following substances to Penalty Group 2-A:</p> <p>Tetramethylcyclopropylindole: any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent, including:</p> <ol style="list-style-type: none"> (1) A-834,735; (2) A-796,260; (3) AB-005; (4) UR-144; (5) 5-Bromo UR-144; (6) 5-Chloro UR-144; and (7) 5-Fluoro UR-144 (Other name: XLR-11). <p>Tetramethylcyclopropane-thiazole carboxamide: any compound structurally derived from 2,2,3,3-tetramethyl-N-(thiazol-2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent, including: A-836,339;</p>	<p>2/19/2015 – referred to Criminal Jurisprudence Committee.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Texas 2015 HB 597 (Continued) (Page 4 of 4)	Adds the following substances to Penalty Group 2-A: Quinolinyndolecarboxylate: any compound structurally derived from quinolin-8-yl indole-3-carboxylate by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the quinoline ring to any extent, including: <ul style="list-style-type: none"> (1) BB-22; (2) 5-Fluoro PB-22; (3) PB-22. 	2/19/2015 – referred to Criminal Jurisprudence Committee.
Texas 2015 HB 1424	Similar to 2015 HB 488.	3/9/2015 – referred to Criminal Jurisprudence Committee.
Texas 2015 HB 2880 (Page 1 of 4)	Adds the following substances to Penalty Group 2: <ul style="list-style-type: none"> (1) 5-methoxy-alpha-methyltryptamine; (2) (2-aminopropyl) Benzofuran (trade or other name: APB); (3) (2-aminopropyl) Dihydrobenzofuran (trade or other name: APDB); (4) [3-(3-Carbamoylphenyl)phenyl]N-cyclohexyl Carbamate (trade or other name: URB-597); (5) Fentanyl mimetic substances structurally derived from fentanyl by substitution in the phenethyl group, substitution in the piperidine ring, substitution in the aniline ring, replacement of the phenyl portion of the phenethyl group, replacement of the N-Propionyl group, or any combination of those substitutions or replacements; (6) Hydroxyphencyclidine (trade or other name: HO-PCP); 	3/16/2015 – referred to Criminal Jurisprudence Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
<p>Texas</p> <p>2015 HB 2880 (Continued) (Page 2 of 4)</p>	<p>Adds the following substances to Penalty Group 2:</p> <p>N-methyltryptamine mimetic substances structurally derived from N-methyltryptamine by substitution at the nitrogen atom, substitution at the indole ring, substitution at the alpha carbon, substitution at the beta carbon, or any combination of those substitutions, excluding 5-methoxy-N-Acetyltryptamine, and including, by example:</p> <ol style="list-style-type: none"> (1) ACO-DMT; (2) Baeocystine; (3) BROMO-DALT; (4) DIPT; (5) DMT; (6) DPT; (7) HO-DET; (8) HO-DIPT; (9) HO-DMT; (10) HO-DPT; (11) HO-MET; (12) MEO-DALT; (13) MEO-DET; (14) MEO-DIPT; (15) MEO-DPT; (16) MEO-NMT; (17) MET; (18) NMT; and (19) Norbufotenin; (20) Parahexyl (some trade or other names: 3-Hexyl-1- hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d] pyran; Synhexyl). <p>Phencyclidine mimetic substances structurally derived from phenylcyclohexylpiperidine by substitution at the phenyl ring, substitution at the piperidine ring, substitution at the cyclohexyl ring, replacement of the phenyl ring, or any combination of those substitutions or replacements, including, by example, compounds</p>	<p>3/16/2015 – referred to Criminal Jurisprudence Committee.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Texas 2015 HB 2880 (Continued) (Page 3 of 4)	such as: (1) Amino-PCP; (2) BCP; (3) Bromo-PCP; (4) TCPY (5) BTCP; (6) Chloro-PCP; (7) Fluoro-PCP; (8) HO-PCP; (9) MEO-PCP; (10) Methyl-PCP; (11) Nitro-PCP; (12) OXO-PCP; (13) PCE; (14) PCM; (15) PCPY; (16) TCP; (17) TCPY Aminoindane mimetic substances structurally derived from Aminoindane by substitution at the nitrogen atom, substitution at the indane ring, replacement of the amino group with another N group or any carbon, or any combination of those substitutions or replacements, including, by example, compounds such as: (1) AMMI; (2) IAI; (3) MDAI; (4) MMAI (5) Fluoroamphetamine; (6) Fluoromethamphetamine; (7) Methiopropamine; (8) 2-(Methoxyphenyl)-2- (ethylamino) cyclohexanone(methoxetamine); (9) 2-(Methoxyphenyl)-2- (methylamino) cyclohexanone(methoxyketamine); (10) Methoxyphencyclidine (trade or other name: MEO-PCP); (11) Alpha-Pyrrolidinovalerothiophenone (trade or other name: alpha-PVT);	3/16/2015 – referred to Criminal Jurisprudence Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Texas 2015 HB 2880 (Continued) (Page 4 of 4)	Adds the following substances to Penalty Group 2-A: 3-Adamantoylindole, with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent or in the adamantyl ring to any extent, including, by example, compounds such as AB-001; Indazole-3-Carboxamide with substitution at the nitrogen atom of the indazole ring, whether or not further substituted in the indazole ring to any extent or in the adamantyl ring to any extent, including, by example, compounds such as: (1) AB-Fubinaca; (2) AB-Pinaca; (3) AKB-48; (4) Apinaca; (5) Fluoro-AKB-48; N-(adamantyl)-indole-3-Carboxamide, with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent or in the adamantyl ring to any extent, including, by example, compounds such as SDB-001; 8-Quinoliny-indole-3-carboxylate with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent or in the quinoline ring to any extent, including, by example, compounds such as: (1) Fluoro-PB-22; (2) PB-22.	3/16/2015 – referred to Criminal Jurisprudence Committee.
Texas 2015 HB 3889	Adds the following substances to Penalty Group 2: (1) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3- carboxamido)-3,3-dimethylbutanoate; (2) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5- fluoropentyl)-1H-indole-3-carboxamide; (3) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5- fluoropentyl)-1H-indazole-3-carboxamide.	3/23/2015 - referred to Criminal Jurisprudence Committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Texas 2015 SB 172	Companion bill to 2015 HB 595.	3/24/2015 – passed House.
Texas 2015 SB 173	Companion bill to 2015 HB 597.	3/24/2015 – passed House.
Texas 2015 SB 199	Companion bill to 2015 HB 488.	1/27/2015 – referred to Criminal Justice Committee.
Texas 2015 SB 1583	<p>Adds a provision to Schedule I that it includes “any synthetic cannabinoid or cathinone designer drug that is not regulated by the United States Food and Drug Administration or by the laws of this state but that is similar by structure or pharmacological effect to a Schedule I or II controlled substance that is regulated under federal law or the laws of this state.”</p> <p>Examples include “substances that are generated using a three-component pharmacophore model. Synthetic cannabinoid designer drugs that contain one or more components of a controlled substance in Schedule I or II under federal or state law are analogues of Schedule I or II controlled substances.”</p>	3/23/2015 – referred to Health and Human Services Committee.
Utah	No pending proposed legislation.	
Vermont	No pending proposed regulations.	

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
Virginia 2015 HB 1564	Adds the following substances to Schedule I: (1) 3,4-methylenedioxy-N,N-dimethylcathinone (other names: Dimethylone, bk-MDDMA); (2) N-3-methyl-1-(2-hydroxy-2-phenethyl)4-piperidyl]-N-phenylpropanamide (other name: beta-hydroxy-3-methylfentanyl); (3) N-(4-fluorophenyl)-N-1-(2-phenethyl)-4-piperidinyl]-propanamide; (4) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (other name: AB-CHMINACA); (5) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide (other name: 5-fluoro-AMB).	2/23/2015 – enrolled bill sent to Governor; action deadline 3/29/2015.
Virginia 2015 SB 1380	Companion bill to 2015 HB 1564.	2/26/2015 – enrolled bill sent to Governor; action deadline 3/29/2015.
Washington 2015 HB 1552	Adds provision that industrial hemp is excepted from the categories of controlled substances in the schedules.	2/24/2015 – committee hearing.
Washington 2015 SB 5434 (Page 1 of 3)	Adds the following synthetic cannabimimetics substances to Schedule I: Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;	1/21/2015 – first reading and referred to Committee on Health Care.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Washington</p> <p>2015 SB 5434 (Continued) (Page 2 of 3)</p>	<p>Adds the following synthetic cannabimimetics substances to Schedule I:</p> <p>Naphthylmethyloindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;</p> <p>Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;</p> <p>Naphthylmethyloindenes: Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;</p> <p>Phenylacetyloindoles: Any compound containing a 3-phenylacetyloindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;</p>	<p>1/21/2015 – first reading and referred to Committee on Health Care.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Washington</p> <p>2015 SB 5434 (Continued) (Page 3 of 3)</p>	<p>Adds the following synthetic cannabimimetics substances to Schedule I:</p> <p>Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent;</p> <p>Benzoylindoles: Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;</p> <p>(viii) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone: Some trade or other names: WIN 55,212-2;</p> <p>Adds (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo[c]chromen-1-ol: Some trade or other names: HU-210 to Schedule I.</p>	<p>1/21/2015 – first reading and referred to Committee on Health Care.</p>
<p>Washington</p> <p>2015 SB 5673</p>	<p>Adds the following provision to the definition of tetrahydrocannabinols in Schedule I:</p> <p>“That is chemically synthesized and either:</p> <ol style="list-style-type: none"> (1) Has been demonstrated to have binding activity at one or more cannabinoid receptors; or (2) Is a chemical analog or isomer of a compound that has been demonstrated to have binding activity at one or more cannabinoid receptors.” 	<p>3/24/2015 – executive action taken in Committee on Commerce & Gaming.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>West Virginia</p> <p>2015 HB 2931</p>	<p>Adds the following hallucinogenic substances to Schedule I:</p> <ul style="list-style-type: none"> (1) N-(2-Methoxybenzyl)-4-bromo-2, 5-dimethoxyphenethylamine [25B-NBOMe]; (2) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine [25C-NBOMe]; (3) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine [25I-NBOMe]; <p>Adds the following tryptamines to Schedule I:</p> <ul style="list-style-type: none"> (1) 5- methoxy- N- methyl-N-isopropyltryptamine (5-MeO-MiPT); (2) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); (3) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT) (4) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); (5) 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT); (6) 5-methoxy-α-methyltryptamine (5-MeO-AMT); (7) 4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT); (8) 4-hydroxy Diethyltryptamine (4-HO-DET); (9) 5- methoxy- N,N- diallyltryptamine (5-MeO-DALT); (10) 4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT); (11) 4-hydroxy Diethyltryptamine (4-HO-DET). <p>Adds the following substituted amphetamines to Schedule I:</p> <ul style="list-style-type: none"> (1) 2-Fluoroamphetamine (2) 3-Fluoroamphetamine (3) 4-Fluoroamphetamine (4) 2-chloroamphetamine (5) 3-chloroamphetamine (6) 4-chloroamphetamine (7) 2-Fluoromethamphetamine (8) 3-Fluoromethamphetamine (9) 4-Fluoromethamphetamine (10) 4-chloromethamphetamine. 	<p>3/10/2015 – read first time in Senate after passage in House.</p>
<p>Wisconsin</p>	<p>No pending proposed legislation.</p>	

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

State and Bill Number	Description	Status/Date of Last Action
<p>Wyoming</p> <p>2015 SF 16</p>	<p>Adds the following hallucinogenic substance to Schedule I:</p> <p>(1) 3,4-methylenedioxy-N-ethylcathinone [other names: ethylone].</p> <p>Adds the following synthetic cannabinoids to Schedule I:</p> <p>(1) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide [other names: AB-CHMINACA];</p> <p>(2) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone [other names: THJ-2201];</p> <p>(3) 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester [other names: BB-22].</p> <p>Adds the following stimulants to Schedule I:</p> <p>(1) 4-methyl-N-ethylcathinone [other names: 4-MEC; 2-(ethylamino)-1-(4-ethylphenyl)propan-1-one];</p> <p>(2) 4-methyl-alpha-pyrrolidinopropiophenone [other names: 4-MePPP; MePPP; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)propan-1-one];</p> <p>(3) Alpha-pyrrolidinopentiophenone [other names: alpha-PVP; alpha-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one];</p> <p>(4) Butylone [other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one];</p> <p>(5) Pentedrone [other names: alpha-methylaminovalephorophenone; 2-(methylamino)-1-phenylpentan-1-one];</p> <p>(6) Pentylone [other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one];</p> <p>(7) Naphyrone [other names: naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one];</p> <p>(8) Alpha-pyrrolidinobutiophenone [other names: alpha-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one].</p>	<p>3/4/2015 – signed by Governor (2015 Wyo. Laws Ch. 136); effective immediately.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of March 24, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.